Delphi Teaming Profiles
This page is designed to help facilitate connections between prospective proposers, which ARPA-H anticipates will be necessary to achieve the Delphi program. Prospective performers are encouraged (but not required) to form teams with varied technical expertise to submit a proposal.
If either you or your organization are interested in teaming, please create a profile via the ARPA-H Solutions site linked below. Your details will then be added to this page, which is publicly available.
Please note that by publishing the teaming profiles list, ARPA-H is not endorsing, sponsoring, or otherwise evaluating the qualifications of the individuals or organizations included here. Submissions to the teaming profiles list are reviewed and updated periodically.
Delphi Teaming Profiles
To narrow the results in the Teaming Profiles List, please use the input below to filter results based on your search term. The list will filter as you type.
| A | AA | AAA | AAA | AAA | AAA | AAA |
| Alexander Yoshikawa | Adaptyx Biosciences | ay@adaptyx.bio | Menlo Park, CA | Adaptyx Biosciences has demonstrated continuous monitoring of multiple biomarkers in humans outside laboratory settings, spanning hormones, metabolites, and drugs. Building on 17 years of foundational academic research, our high-throughput molecular switch foundry produces optimized sensors in weeks, achieving high sensitivity, specificity, and robustness to environmental factors. We are actively conducting IRB-approved human studies through our in-house clinical infrastructure. | Seeking TA1 partners with proven expertise in chiplet packaging, heterogeneous integration, ultra-low-power IC design, and secure wireless communication with post-quantum cryptography. Also seeking TA3 partners in hermetic encapsulation and biocompatible coatings, and TA4 partners in clinical trial design and FDA regulatory strategy. We bring human-demonstrated wet biosensing technology (TA2), a rapid sensor development pipeline, and existing clinical study infrastructure. | TA2: Wet Biosensing Chiplets, TA1: Dry Chiplets unique to Biosensing |
| Michael Rein | AFFOA | michael@affoa.org | Bedford, MA | AFFOA develops advanced fiber systems using thermal draw processes to embed sensing, communication, and electronic functionalities directly into fibers and textiles. Our research focuses on scalable textile integration of distributed sensors, chiplet integration into flexible fibers and textiles, and robust encapsulation strategies for durability. We enable modular, low-power wearable systems for continuous physiological and biochemical monitoring. | AFFOA seeks partners with expertise in chiplet design (low-power electronics, secure communication), wet biosensing for molecular detection, and advanced encapsulation compatible with microelectronics and scalable manufacturing. | TA3: Biocompatible Encapsulation |
| Michael Polk | Allez Health | mpolk@allezhealth.com | San Diego, CA | Biosensors for metabolic sensing for chronic disease management and wellness | Physiologic sensors and advanced algorithms | TA2: Wet Biosensing Chiplets, TA4: Human Factors Testing or Clinical Trial |
| Esko Mikkola | Alphacore, Inc. | esko.mikkola@alphacoreinc.com | Tempe, AZ | Alphacore develops advanced mixed-signal CMOS ICs and chiplet-based SoCs, specializing in ultra-low-power analog front ends, data converters, and secure communications. Our work focuses on energy-efficient power management, sensor interfaces, and interoperable chiplet architectures for edge systems. We target scalable, manufacturable solutions enabling continuous sensing and secure data transmission. | We seek partners across Delphi TAs to form a complete, integrated team. For TA1, we are interested in advanced packaging/interconnect, ultra-low-power power management, and secure communications. We also seek TA2 biosensing innovators, TA3 biocompatible encapsulation experts, and TA4 clinical/human factors partners to enable end-to-end system development and validation. | TA1: Dry Chiplets unique to Biosensing, TA2: Wet Biosensing Chiplets |
| Muyiwa Oni | AltruMed | info@altru-med.com | Philadelphia, PA | We develop wearable biosensing platforms with an emphasis on modular, scalable system design. We bring expertise in system integration, multimodal sensing, biocompatible packaging, and human factors validation. Our current work focuses on extending a clinically validated platform to support continuous molecular monitoring. | Seeking a partner with demonstrated capabilities in chiplet design, manufacturing, clean‑room production, and scaling for manufacturing. We have a well‑defined proposal and are looking for a partner to help complete the manufacturing and production side of the chiplet architecture. | TA1: Dry Chiplets unique to Biosensing, TA2: Wet Biosensing Chiplets, TA3: Biocompatible Encapsulation, TA4: Human Factors Testing or Clinical Trial |
| Chris Loughnane | Analog Devices | chris.loughnane@analog.com | Wilmington, MA | Biosensing, Chip design, low power. | Clinical expertise. Encapsulation. | TA2: Wet Biosensing Chiplets, TA1: Dry Chiplets unique to Biosensing |
| Fred Miller | Arbor Research Collaborative for Health | fred.miller@arborresearch.org | Ann Arbor, MI | Arbor Research Collaborative for Health brings deep expertise in designing and operating Data Coordinating Centers (DCCs) for large-scale clinical studies and pragmatic trials. We focus on secure, scalable and compliant (FDA 21 CFR Part 11) data integration, trial operations, participant protection, and real-time analytics to support complex multi-site biomedical innovation. These capabilities enable next-generation health technologies across many body system areas. | We are seeking partners with strengths across TA1, TA2, and TA3. | TA4: Human Factors Testing or Clinical Trial |
| Jim Friel | Arete | jfriel@arete.com | Falls Church, VA | Arete's relevant work is in design and integration of complex, low-SWAP electronics systems for difficult environments, from putting sensors deep in the ocean to microsensor-integrated clothing for IARPA SmartePants. | Partners with capabilities in integrated circuit design as well as biosensor design are most welcome. We are interested in teaming as either prime and subcontractor. | TA1: Dry Chiplets unique to Biosensing, TA3: Biocompatible Encapsulation |
| Arindam Sanyal | Arizona State University | arindam.sanyal@asu.edu | Tempe, AZ | Our research is focused on developing ultra-low-power microelectronics for bio-sensors that includes AI for wake-up | We are looking for help with TA2 and TA3 | TA1: Dry Chiplets unique to Biosensing, TA4: Human Factors Testing or Clinical Trial |
| Josh Hihath | Arizona State University | jhihath@asu.edu | Tempe, AZ | We develop electronic single-molecule sensing devices that can be modified to target a range of different potential biomarkers. | We're looking for partners with interesting clinical applications, with specific target analytes. | TA2: Wet Biosensing Chiplets, TA1: Dry Chiplets unique to Biosensing |
| Kaushal Rege | Arizona State University | rege@asu.edu | Tempe, AZ | Biomaterials innovation, wounds, animal models, biocompatibility, drug delivery, nanoparticles, fabrication | Implantable devices | TA3: Biocompatible Encapsulation |
| Feng Yan | Arizona State University | fengyan@asu.edu | Tempe, AZ | working on the device encapsulation with biomass materials | device and materials fabrication | TA3: Biocompatible Encapsulation, TA1: Dry Chiplets unique to Biosensing |
| Josh Hihath | Arizona State University | jhihath@asu.edu | Tempe, AZ | We develop electronic chips that are designed to detect analytes of interest with high-sensitivity, down to the single-molecule level. | Partners with clinical research capabiliites, and interest/expertise in detection of specific targets. | TA2: Wet Biosensing Chiplets, TA1: Dry Chiplets unique to Biosensing |
| JESUS DELGADO | ARQUIMEA USA Inc | jdelgado@arquimea.com | Pasadena, CA | ARQUIMEA has developed novel aptamer-based sensing technologies for real-time, continuous, and reversible monitoring for cortisol and antibiotics, and it is expanding its technology to a broad spectrum of biomolecules, including other hormones and therapeutics drugs, and immunosuppressants. We have developed highly miniaturized biosensors with picomolar sensitivity, leveraging SWV and FET-based transduction, and translated those into wearable devices with clinically relevant performance. | Our work would focus on TA2: Wet Biosensing Chiplets and we are seeking partners to complement our capabilities in engineered chiplet architectures (TA1) and biopackaging (TA3), enabling the development of fully integrated sensing platforms. | TA2: Wet Biosensing Chiplets |
| Kurt Rohloff | Avometric LLC | krohloff@avometric.com | Hoboken, NJ | We are a proven ARPA-H and DARPA performer specializing in applied cryptography and hardware acceleration (ASIC/FPGA) for ultra-low-SWaP Post-Quantum Cryptography (PQC) for secure data collaboration. Leveraging our experience for hardware design and as founders of open-source OpenFHE software library, we excel at translating NIST-compliant lattice-based algorithms (like ML-KEM) into highly constrained hardware to guarantee energy-efficient, quantum-resistant security. | We seek a strong Prime Contractor with proven systems integration and FDA regulatory experience to lead a complete TA1-TA4 Delphi proposal. We are looking to team with experts in TA2 ("wet" continuous biosensors for hormones/cytokines, regenerative surface chemistry) and TA3 (biocompatible, hermetic encapsulation). As the TA1 secure communications lead, we want to integrate our ultra-low-SWaP PQC chiplets into your wearable or ingestible medical device platform. | TA1: Dry Chiplets unique to Biosensing |
| Bill Jackson | Base Pair Biotechnologies, Inc. | bill.jackson@basepairbio.com | Houston, TX | BasePair Bio develops multiplex DNA/RNA-based aptamer panels for measuring protein & immune biomarkers (e.g., cytokines, complement factors, metabolites) in accessible samples (blood, urine, saliva). These reagents generate novel molecular data streams that integrate with sensing platforms and data pipelines to enable real-time and longitudinal monitoring for predictive health modeling. | We seek collaborators developing: 1. Predictive modeling, AI/ML, or digital twin frameworks 2. Wearable/implantable or ingestable sensing platforms 3. Multimodal data integration systems 4. Clinical or operational health prediction tools BasePair can contribute: a. Multiplex aptamer panels for real-time molecular measurement b. Integration into electrochemical, optical, or microfluidic sensing platforms c. Aptamers for enhancing sensor biocompatibility/acceptance | TA2: Wet Biosensing Chiplets, TA3: Biocompatible Encapsulation |
| Tom Mera | Battelle Memorial Institute | mera@battelle.org | Columbus, OH | Battelle offers a wide range of biotechnology, science, and engineering capabilities including medical technology development from early feasibility through formal design and a dedicated human centric design team that conducts human factors usability testing. | TBD | TA4: Human Factors Testing or Clinical Trial |
| Ethan Litman | Beth Israel Lahey / BIDMC | elitman@bidmc.harvard.edu | Boston, MA | We are experts in women's reproductive health (pregnancy, fetal medicine, neonatal medicine, menopause) and are seeking collaborators to develop an innovative biosensing platform. We have additional expertise other chronic disease spanning cardiology, immunology, and neurology. With over 400,000 primary care visits annually and 50,000 births we can serve as robust clinical partners. We have expert staff in research compliance, data collection, and recruitment. | We are looking for partners who are seeking to develop innovative solutions that will provide patients and clinicians with real-time biologic data that can be used to alter the trajectory of their disease. Real-time information will lead to rapid diagnosis, decreased health care utilization, an substantial improvement in patient's quality of life. | TA4: Human Factors Testing or Clinical Trial |
| Brian Kelly | Biolinq Incorporated | briankellymd@gmail.com | San Diego, CA | Biolinq uses individually addressable microneedles to create both enzyme-bases and aptamer-based multi-analyte biosensors. Our platform for measuring glucose, activity and sleep is already FDA-approved. | Companies and groups that need multi-analyte sensing capabilities | TA1: Dry Chiplets unique to Biosensing, TA2: Wet Biosensing Chiplets |
| Uros Kuzmanovic | BioSens8, Inc. | uros@biosens8.com | Cambridge, MA | Continuous biosensors engineering and characterization Hardware design and engineering | Advanced biocompatible packaging | TA2: Wet Biosensing Chiplets, TA1: Dry Chiplets unique to Biosensing |
| M Anthony Lewis | BrainChip, Inc. | tlewis@brainchip.com | Laguna Hills, CA | BrainChip’s current research focuses on its 3rd generation of Akida system, an ultra-low-power neuromorphic chip, and a modular chiplet architecture running state-space models for real-time biosensing. This innovative approach is unmatched at the edge in size, power, performance, and cost, delivering high performance for less than 1mW and costing less than $1. BrainChip has demonstrated strong results in LLMs, audio processing, and radar, validating its scalable, real-time AI capability. | BrainChip provides the ultra-low-power neuromorphic AI engine (Akida Gen 3) and seeks partners, including universities, sensor developers, and biomedical companies, to build a complete biosensing wearable. By combining its adaptive, event-based chiplet system with advanced sensing and clinical expertise, the team aims to deliver a modular, real-time health monitoring system aligned with Delphi’s vision. | TA1: Dry Chiplets unique to Biosensing, TA4: Human Factors Testing or Clinical Trial |
| M Anthony Lewis | BrainChip, Inc. | tlewis@brainchip.com | Laguna Hills, CA | BrainChip is a leader in ultra-low-power neuromorphic computing, delivering edge AI solutions that emulate the efficiency and adaptability of the human brain. Our current R&D focuses on advancing event-based processing, sensor fusion, and on-device learning within the Akida™ platform to enable intelligent, autonomous systems. We are applying these capabilities to real-time biosensing and adaptive health monitoring applications that demand efficient, always-on processing close to the sensor. | BrainChip seeks multidisciplinary partners to develop fully integrated devices addressing all Technical Areas. Our focus under TA1 (dry chiplets) complements collaborators specializing in chiplet integration, “wet” biosensor development, encapsulation, and wireless communication technologies for secure, low-power data and power transfer. We aim to contribute neuromorphic AI compute to build both minimally invasive and non-invasive wearable platforms for medical and wellness applications. | TA1: Dry Chiplets unique to Biosensing, TA1: Dry Chiplets unique to Biosensing |
| Mehdi Saligane | Brown University | mehdi_saligane@brown.edu | Providence, RI | We develop ultra-low-power bioelectronics, miniaturized sensing systems, mixed-signal ICs, and chip-scale platforms for biomedical applications, with interest in AI-enabled rapid sensor development and low-power data interpretation for scalable biosensing systems. Including chip-scale platforms for protein sensing and nucleic-acid-enabled molecular sensing approaches that could support modular wet biosensing chiplets for continuous biomarker monitoring. | We seek partners with strengths in wet biosensing, protein/molecular sensing chemistry, surface functionalization, biocompatible encapsulation, and translational validation. We are particularly interested in teams pursuing wearable or minimally invasive biomarker monitoring and integrating these capabilities with miniaturized, ultra-low-power chiplet-based bioelectronic platforms. | TA1: Dry Chiplets unique to Biosensing, TA2: Wet Biosensing Chiplets |
| Paul Elrif | Caelus | info@caelus-usa.com | Kirkland, WA | Human factors, UX research, usability, product development, software development | We are looking to help with existing work or work you land. As a small business coming from 13.5 years in private industry, we need to build a portfolio of government work, and this looks like a good place for us to start. | TA4: Human Factors Testing or Clinical Trial, TA4: Human Factors Testing or Clinical Trial |
| Gareth Hughes | Caizio | gareth.hughes@caizio.com | Dallas, TX | Caizio develops miniaturized, wearable medical devices and biosensors. Current and previous research include integrating electronic signal measurements and vital sensors for neuropathy, and a handheld fluorometer to assess platelet function. This expertise in wearable sensor integration, microfabrication, and low-power optoelectronics aligns perfectly with Delphi’s objective to build modular, continuous wearable biosensing platforms. | Caizio excels in microfabrication and biosensors but needs partners for Delphi’s remaining Technical Areas (TAs). Key gaps include ultra-low power chiplet architecture and post-quantum secure communications (TA1). We also require experts in biocompatible hermetic encapsulation at the chiplet scale (TA3), and clinical partners to conduct human factors testing or FDA-regulated clinical trials (TA4) for the integrated device. | TA2: Wet Biosensing Chiplets, TA3: Biocompatible Encapsulation, TA1: Dry Chiplets unique to Biosensing |
| Dr. John Currie | Cambridge Medical Technologies | john.currie@cambridgemedtech.com | Rockville, MD | CMT is pioneering a transformative leap in combat casualty and critical care medicine with its advanced biosensor platform. Originally founded on research funded by DARPA, the Army Research Office, and Walter Reed Army Institute of Research, CMT’s mission has been to develop non-invasive, real-time monitoring of blood chemistry for soldiers in the field. Our breakthrough technology samples subcutaneous interstitial fluid painlessly and analyzes it outside the body for key biomarkers. | CMT is looking for partners with whom we can develop and field-test a complete Next-Gen advanced medical monitor with vital signs and/or complementary wet chiplet chemistries. Combat medics, first-responders and clinicians can monitor trends in real time, enabling faster, more informed decisions during trauma care, sepsis management, and evacuation triage. In ERs and ICUs, the same platform reduces reliance on repeated blood draws, improves response times, and enhances patient outcomes. | TA2: Wet Biosensing Chiplets |
| Helena Snyder | Cambridge Medical Technologies | helenawsnyder@gmail.com | Rockville, MD | "CMT is pioneering a transformative leap in combat casualty and critical care medicine with its advanced biosensor platform. Originally founded on research funded by DARPA, the Army Research Office, and Walter Reed Army Institute of Research, CMT’s mission has been to develop non-invasive, real-time monitoring of blood chemistry for soldiers in the field. Our breakthrough technology samples subcutaneous interstitial fluid painlessly and analyzes it outside the body for key biomarkers. | CMT is looking for partners with whom we can develop and field-test a complete Next-Gen advanced medical monitor with vital signs and/or complementary wet chiplet chemistries. Combat medics, first-responders and clinicians can monitor trends in real time, enabling faster, more informed decisions during trauma care, sepsis management, and evacuation triage. In ERs and ICUs, the same platform reduces reliance on repeated blood draws, improves response times, and enhances patient outcomes. | TA2: Wet Biosensing Chiplets, TA1: Dry Chiplets unique to Biosensing |
| Oleh Smutok | Clarkson University | osmutok@clarkon.edu | Potsdam, NY | We propose a microinvasive wearable electrochemical biosensing platform leveraging AI-designed chimeric glucose dehydrogenase (PQQ-GDH) protein switches. Circularly permuted PQQ-GDH fused with ligand-binding domains converts analyte binding into amplified electrochemical signals, enabling ultrasensitive, multiplexed real-time detection of drugs and hormones. Multichannel electrode functionalization supports selective, simultaneous monitoring of key biomarkers. | We are seeking an industry partner with expertise in multichannel electrode array construction, including the development of integrated arrays for simultaneous, multiplexed detection of multiple analytes. Experience in device interfacing is also essential, particularly in designing low-power, portable readout systems compatible with smartphones. | TA2: Wet Biosensing Chiplets, TA2: Wet Biosensing Chiplets |
| Alethea Wieland | Clinical Research Strategies LLC | alethea@clinicalresearchstrategies.com | Wexford, PA | Clinical Research Strategies is an executive management consultancy and Clinical Contract Research Organization (CRO) with experience on ARPA-H programs as key contributors to 1) quality assurance, risk management and custom QMS builds per ISO/FDA requirements; 2) all things regulatory strategy, pathways, and submissions (INTERACT, Pre-IND/Q-Subs, IND/IDE, 510k PMA/NDA/BLA, de novo, LDTs/assays, etc.); 3) Human Factors; and 4) Full Service Clinical Trials. | Clinical Research Strategies LLC | TA4: Human Factors Testing or Clinical Trial |
| David Dandy | Colorado State University | dandy@colostate.edu | Fort Collins, CO | As a R1 land grant university we focus on a broad array of research activities, from agriculture to energy, to infectious diseases, to water and environment. In the context of Delphi, the specific focus area is development of biosensing platforms for detection of nucleic acids, proteins, and small molecules. Our core team consists of Profs. Chuck Henry (chemistry), Brian Geiss (microbiology), and David Dandy (chemical and biological engineering). | Our expertise is in point of need microfluidic platform development using colorimetric, electrochemical, or chemiluminescent signal readout. What we lack is electronics and computer science expertise. The TPPs described in the Delphi announcement include our core strengths, but also require possible expertise in optoelectronics, communications, electronics hardware. | TA2: Wet Biosensing Chiplets |
| Swathi Manda | Continuity Technologies Inc. | swathi@continuity.bio | Mountain View, CA, CA | Continuity develops enabling interfaces for continuous access to deep biological information from within the body. Our current focus is wet biosensing in interstitial fluid for proteins, metabolites, ions, and drugs, including molecular recognition, low-power electrochemical transduction, surface/passivation strategies, and biocompatible integration for wearable microneedle based systems. | We seek partners in ultra-low-power chiplets, secure medical data transmission, hermetic biocompatible packaging, wearable/skin-integration, in-vivo testing, and human factors or clinical validation. Our strongest contribution is in wet biosensing. We are looking to build integrated TA2/TA3-centered teams with complementary TA1 and TA4 expertise. | TA2: Wet Biosensing Chiplets, TA3: Biocompatible Encapsulation |
| Nicholas Williams | Continuum Diagnostics LLC | nicholasxdw@gmail.com | Irvine, CA | Continuum Diagnostics has developed a printing process and fabrication methodology for biomedical electrochemical sensors and introducer assemblies, enabling rapid, on-demand manufacturing of configurable multi-analyte sensing platforms. This print-to-order approach leverages custom-formulated inks. The result is a scalable, low-cost production pipeline capable of generating application-specific biosensor chiplets without retooling or redesigning the core manufacturing platform. | We are looking for partners on TA3 (biocompatible encapsulation) and TA4 (Human factors and clinical) | TA2: Wet Biosensing Chiplets, TA1: Dry Chiplets unique to Biosensing |
| Alyosha Molnar | Cornell University | am699@cornell.edu | Ithaca, NY | Low power IC design for biosensing and communications, with reconfigurability. Post-processing of CMOS chiplets for hetero-integration of optical and electrochemical elements, including encapsulation. | Definitely TA4, but probably a larger team overall. | TA1: Dry Chiplets unique to Biosensing, TA3: Biocompatible Encapsulation |
| Wei Ouyang | Dartmouth College | wei.ouyang@dartmouth.edu | Hanover, NH | Our expertise is in biosensing and system-level integration. We have developed microneedle-based electrochemical sensors for in vivo monitoring of biochemical markers in various organs (Nature BME 2026). We are currently developing self-adaptive electrochemical sensors for long-term, in vivo monitoring. One example includes a minimally drifting EAB sensor that maintains functionality for multiple weeks. | All technical areas. For TA2, expertise in macromolecule monitoring would be a plus. | TA2: Wet Biosensing Chiplets, TA3: Biocompatible Encapsulation |
| Tam Vu | Dartmouth College | tam.n.vu@dartmouth.edu | Hanover, NH | Dartmouth's team combines expertise in wearable health sensing, electrochemical biosensor design, microneedle-based interstitial fluid (ISF) monitoring, flexible electronics, and clinical-grade signal processing. Our research group integrates multi-modal sensor data with edge ML for real-time health monitoring. | We seek TA1 partners with custom ASIC/chiplet design for multi-channel electrochemical readout, low-power wireless, and post-quantum cryptography. For TA2, we seek collaborators with electrochemical aptamer-based (E-AB) sensor development, aptamer selection/engineering (SELEX), and anti-fouling strategies for in-vivo ISF biosensing. | TA1: Dry Chiplets unique to Biosensing, TA3: Biocompatible Encapsulation |
| Eugene Chan | DNA Medicine Institute | eugene@rhealth.com | Bedford, MA, MA | We specialize in advanced miniaturized nanostrips that allow non-contact measurement of biological analytes. Our organization is known for development of advanced biological sensing capabilities and we have had a history of developing TRL = 9 technologies for NASA and medical applications. We have a deep record of innovation and have multiple patents on our miniatured nanoscale test strips (nanostrips) which allow for mutliplexed optical sensing, thus simplifying the wet-dry interface. | We are looking for expertise in chip design and clinical trials. Unique partners that have this expertise should reach out. | TA2: Wet Biosensing Chiplets |
| Alket Mertiri | Draper | amertiri@draper.com | Cambridge, MA | At Draper, we revolutionize drug discovery and development with cutting-edge microphysiological systems and bioprocessing technologies. Our expertise enhances disease diagnostics, paving the way for advanced therapeutic medical devices tailored for both civilian and military critical care. We are at the forefront of synthetic biology, driving innovation across medical, biosecurity, and manufacturing sectors. | We are looking for partners that can handle clinical studies for our cutting edge technology. | TA1: Dry Chiplets unique to Biosensing, TA3: Biocompatible Encapsulation |
| Kerrin Encarnacion | Draper | kpoole@draper.com | Cambridge, MA | Draper excels in multidisciplinary engineering solutions, with expertise in biosensor design and integrated device development. Capabilities include 2.5D/3D electronics packaging, chiplet design, and biosensor design and implementation. Draper has an extensive track record of developing next generation medical device technologies including implantable drug delivery systems and other therapeutic and diagnostic devices for applications in critical care and physiological monitoring. | Draper is open to various teaming arrangements. | TA3: Biocompatible Encapsulation |
| Shawn Lawson | Edgnxus | edgenexustech@outlook.com | 1024 Greendale Rd, KY | EDGNXUS develops wearable biosensing systems integrated into clothing to enable continuous, non-invasive physiological monitoring. Our research focuses on dry biosensing chiplets, embedded sensor systems, biocompatible encapsulation for wearable electronics, and AI-driven data interpretation for real-time health insights and performance monitoring. | We seek partners with expertise in biosensor chip design, flexible electronics, advanced packaging/encapsulation, clinical validation, and AI-driven physiological data analysis. Collaborators with experience in medical device development, wearable systems, and translational research will help accelerate validation and deployment of scalable biosensing platforms. | TA1: Dry Chiplets unique to Biosensing, TA3: Biocompatible Encapsulation |
| Spencer Matonis | Edulis Therapeutics, Inc. | spencer@edulis.xyz | Nashville, TN | Edulis Therapeutics has developed the first toolset for long-term intestinal implants for sustained drug delivery. We have validated this technology in pig models and are interested in expanding it's application to human health monitoring via the Project Delphi grant opportunity. | We are primarily looking ECE experts who have experience with ultra-compact, hermetically-sealed, implantable bioelectronics (e.g. BCIs, pacemakers, spinal stimulators, etc.). We currently have expertise around biosensors, power management, animal studies, hospital partners, and commercialization. | TA4: Human Factors Testing or Clinical Trial, TA2: Wet Biosensing Chiplets |
| Babak Mahmoudi | Emory University | b.mahmoudi@emory.edu | Atlanta, GA | Our research develops embedded, AI-driven sensing and closed-loop systems for precision medicine, integrating dry chiplet architectures with hardware–algorithm co-design to enable scalable, low-power edge intelligence. Our research spans energy harvesting, low-power sensing, secure communication, and distributed AI that support real-time inference and seamless integration with clinical and wearable platforms. | We seek partners with expertise in “wet” biosensing chiplets, including novel biological recognition elements and cleanroom-compatible surface passivation strategies. We also prioritize collaborators advancing biocompatible, hermetic encapsulation that enables stable biointerfaces while protecting dry chiplets from moisture, supporting long-term, implantable or wearable system reliability. | TA1: Dry Chiplets unique to Biosensing, TA4: Human Factors Testing or Clinical Trial |
| benoit tucoulat | Empatica | btu@empatica.com | Boston, MA | Empatica is a digital health company developing clinically validated wearable technologies for continuous physiological monitoring. Our focus includes biosensing, AI-driven analytics, and remote patient monitoring. We have brought multiple devices to market, including the EmbracePlus watch and EmbraceMini, supporting Epilepsy and Parkinson monitoring and research applications. | We are seeking partners with strong expertise in electrochemical sensors or microfluidics to support the development of advanced biosensing capabilities and integration with wearable platforms. | TA1: Dry Chiplets unique to Biosensing, TA2: Wet Biosensing Chiplets |
| David Crowley | Empatica | dcr@empatica.com | Boston, MA | Empatica is a digital health company developing clinically validated wearable technologies for continuous physiological monitoring. Our focus includes biosensing, AI-driven analytics, and remote patient monitoring. We have brought multiple devices to market, including the EmbracePlus watch and EmbraceMini, supporting seizure monitoring, Parkinson’s disease care, and research applications. | Empatica seeks partners with expertise in wet biosensing chiplet integration and electrochemical transduction (TA2); biocompatible encapsulation materials and processes for wearable and skin-interfacing devices (TA3); biofunctionalization and antibody/aptamer surface chemistry; and miniaturized analog front-end electronics. We welcome collaborators in flexible biosensor fabrication, polymer encapsulation, and clinical validation aligned with Delphi program goals. | TA1: Dry Chiplets unique to Biosensing, TA4: Human Factors Testing or Clinical Trial |
| Sriram Muthukumar | EnLiSense LLC | sriramm@enlisense.com | Allen, TX | EnLiSense develops non-invasive, wearable sweat-based biosensors for real-time biomarker monitoring. Key products include CORTI (cortisol/melatonin for stress and sleep), IBD AWARE (inflammatory gut markers like calprotectin and CRP), and a multi-biomarker software platform. EnLiSense's sweat-based sensing of immune/inflammatory markers and hormones maps directly onto DELPHI's "wet" biosensor chiplet goals, and its multi-biomarker software aligns with modular, reconfigurable architecture goals. | We are looking for partners for TA1 and TA3. | TA2: Wet Biosensing Chiplets, TA4: Human Factors Testing or Clinical Trial |
| Himanshu Misra | EnlitenAI | himanshu@enlitenai.com | San Francisco, CA | EnlitenAI is building an AI-powered clinical intelligence platform for neurological care. Device-agnostic, it integrates telemetry from wearables, implantables and ingestibles, and real-world data to generate patient-specific insights that guide treatment optimization and titration. While initially focused on epilepsy, the platform is extensible across neurobehavioral disorders. | We are looking for help from partners in areas TA1, TA2 and TA3. | TA4: Human Factors Testing or Clinical Trial |
| Himanshu Misra | EnlitenAI | himanshu@enlitenai.com | San Francisco, CA | EnlitenAI is building an AI-powered clinical intelligence platform for neurological care. Device-agnostic, it integrates telemetry from wearables, implantables and ingestibles, and real-world data to generate patient-specific insights that guide treatment optimization and titration. While initially focused on epilepsy, the platform is extensible across neurobehavioral disorders. | Support on TA1, TA2 & TA3 | TA4: Human Factors Testing or Clinical Trial |
| Alexander Aranyosi | Epicore Biosystems | aja@epicorebiosystems.com | Cambridge, MA | We develop wearable bio-sensing platforms that collect and analyze sweat. We have capabilities for measuring a wide range of analytes using colorimetric and bioelectrical sensing. | We are looking for partners with expertise in "dry" chiplet design for power management and communication. | TA2: Wet Biosensing Chiplets, TA3: Biocompatible Encapsulation, TA4: Human Factors Testing or Clinical Trial |
| Mark Lehmkuhle | Epitel | lehmkukhle@epitel.com | Salt Lake City, UT | Epitel has developed REMI, an FDA-cleared wireless, wearable EEG sensor system designed to record long-term EEG. REMI is currently used commercially for the differential diagnosis of electrographic seizure disorders. Our expertise are in efficient, low-power, wireless transmission protocols for wearable medical devices, cloud integration and workflow, and computational algorithm engineering to support continuous biosignals. | We are looking for TA2 partners with working “wet” biosensing systems who could benefit from wireless integration with electroencephalography as part of a larger cloud-based platform with the goal of clinical study/trial validation. | TA1: Dry Chiplets unique to Biosensing |
| Helena de Puig | ExtRNA | Helena@externa.bio | Somerville, MA, MA | ExtRNA is a synthetic biology company developing programmable biologics and biosensors by expanding the genetic code to incorporate noncanonical amino acids into proteins. Its cell-free translation platform enables rapid discovery and engineering of proteins and nanosensors with novel sensing chemistries for diagnostics and molecular monitoring. Key team publications for this ARPA-H call (biosensors): Nat Biomed Eng (2026, 2022), Nat. Comms. (2024), Sci. Adv. (2021) & Nat. Biotech. (2021). | Externa seeks partners with expertise in semiconductor or MEMS biosensor fabrication, microfluidic sample handling, wearable or implantable device engineering, and clinical validation. Ideal collaborators will integrate biochemical sensing modules with electronics and packaging to enable scalable, multiplexed biosensing platforms. | TA2: Wet Biosensing Chiplets, TA1: Dry Chiplets unique to Biosensing |
| Theresa Neil | Femovate | theresa@femovate.com | San Jose, CA, CA | Femovate focuses on the product design, validation, and commercialization of next-generation women’s health technologies. We have supported the launch of 100+ commercial healthcare products, and our work has helped clients achieve 24 FDA clearances, de novo classification and break-through designations. As a Spoke in the ARPA-H Customer Experience Hub, we provide user insight, product design, and HF testing to accelerate adoption of novel biosensing systems, wearables and SaMD. | We are looking to partner with teams building novel biosensing, chiplet architectures, and biocompatible systems who need support translating technology into commercially viable platforms or products. As part of the ARPA-H CX Hub, we help teams generate user evidence, design engaging patient and consumer experiences, validate usability, and integrate into clinical workflows. Ideal partners are developing sensing modalities and need a CX partner with deep women's health domain expertise. | TA4: Human Factors Testing or Clinical Trial |
| Sachin Junnarkar | Field Viewers Inc | junnarkar@fieldviewers.com | Austin, TX | Field Viewers Inc. focuses on vertically integrated sensing, advanced ASICs, mixed-signal chip design, chiplet architectures, and semiconductor packaging. Key research areas include: High-performance multichannel readout ASICs and FPGAs Silicon photonics for optical interconnects (via AIM Photonics SDK access) Advanced packaging and heterogeneous integration for reliable, low-SWaP systems | Specifically seeking know-how in: Biochemical sensing of low-concentration markers (hormones, cytokines, drug levels) Surface functionalization and electrochemical/affinity-based transduction Wet interface design for robust, long-term body-fluid interfacing Reagent stability and selective molecular recognition | TA1: Dry Chiplets unique to Biosensing, TA4: Human Factors Testing or Clinical Trial |
| James Siegenthaler | Fraunhofer USA Center Midwest | jsiegenthaler@fraunhofer.org | East Lansing, MI | Fraunhofer USA, Inc. is a 501(c)(3) non-profit bridging the gap between research and industry by scaling new technologies. Center Midwest (CMW): Located at Michigan State University, CMW specializes in diamond growth and diamond-based chemical sensing for healthcare, environmental monitoring, and neuroscience. Center for Manufacturing Innovation (CMI): Based at Boston University, CMI scales academic research into industrial medical devices, instruments, and in vitro diagnostics. | With strong expertise in biosensing, and wet biosensing, we are looking for collaborators with strong expertise in both dry chip ACIS incorporation, low power interfaces, and human trials | TA2: Wet Biosensing Chiplets, TA3: Biocompatible Encapsulation |
| Anand Navalgund | G-Tech Medical | anand.navalgund@gmail.com | Mountain View, CA | Expertise in TA2 and TA4. Developer and inventor of the wearable wireless patch for longitudinal monitoring of GI motility. Specialize in isolating low-amplitude GI electrical signals with low-power hardware, and navigating FDA 510(k) pathways for minimally invasive, multi-day diagnostic wearables. My research identified electrical signatures to differentiate healthy vs. disease states in gastroparesis, Crohn's diseases and detection of post-operative ileus. | TA1 (Dry Chiplet) and TA3 Leads: Partners with expertise in ultra-low power management and secure communications (ideally post-quantum) to provide the foundational architecture and Biocompatible encapsulation. | TA2: Wet Biosensing Chiplets, TA4: Human Factors Testing or Clinical Trial |
| Alex Abramson | Georgia Tech | aabramson6@gatech.edu | Atlanta, GA | Our lab engineers novel ingestible devices, including developing platform technologies for ingestible sensors such as capsules and communication methods. We also test these devices in large animal endoscopy models in our own lab. We have over a dozen patents on ingestible systems, and our pills have reached clinical trials. Our work has been published in Science, Nature, Nature Medicine, Nature Electronics, and other prestigious journals. | Our lab is looking to support chip designers by building and testing ingestible capsules that incorporate the novel chips they develop. | TA3: Biocompatible Encapsulation |
| Avni Argun | Giner, Inc. | aargun@ginerinc.com | Newton, MA | Giner develops electrochemical biosensors and bioelectronic platforms for continuous or frequent monitoring in minimally invasive formats. Our work includes enzyme and aptamer based assays for peptide hormones, opioids, and alcohol, with expertise in ISF and saliva sensing, implantable microsensors, sensor miniaturization, and modular architectures. We also use direct electrochemical methods for detecting THC, HIV antiretrovirals, and antibiotics. | We seek prime contractors and device teams needing wet electrochemical or enzymatic biosensor expertise for DELPHI. We are especially interested in partners with selected biomarkers or assays suited for continuous measurement who need a minimally invasive, ISF-capable sensor platform. We also welcome partners with clinical study capabilities, biocompatible membrane and encapsulation expertise, and secure device communications capabilities. | TA2: Wet Biosensing Chiplets, TA1: Dry Chiplets unique to Biosensing |
| Vincent Friebe | GrapheneDx | v.friebe@sapphiros.com | Boston, MA, MA | GrapheneDx develops graphene-based biosensing chiplets enabling rapid, multiplexed, digital diagnostics at the point of care. Our GFET platform directly converts biomolecular binding into electrical signals, delivering lab-grade sensitivity in minutes without labels or optics. Wafer-scale manufacturing enables low-cost, scalable deployment across clinical, consumer, and environmental applications. | We seek academic partners developing novel assays compatible with graphene-based sensing, particularly in protein, nucleic acid, and small molecule detection. We also welcome industry partners in microfluidics, wearable diagnostics, and assay chemistry. Ideal teams bring capabilities in sample-to-sensor integration, enabling translation of advanced assays into scalable, deployable biosensing systems. | TA2: Wet Biosensing Chiplets, TA1: Dry Chiplets unique to Biosensing |
| Wolfgang Hokenmaier | Green Mountain Semiconductor | whokenmaier@greenmountainsemi.com | Burlington, VT | Ultra low power edge computing and data processing including traditional AI algorithms and bio-inspired neuromorphic computing. | Looking to partner with a PI lead who needs an experienced custom ASIC design company. | TA1: Dry Chiplets unique to Biosensing |
| Christian OLIVIER | Green Mountain Semiconductor Inc | colivier@greenmountainsemi.com | Burlington, VT | Green Mountain Semiconductor Inc (https://www.greenmountainsemi.com) is an ASIC design house founded by industry veterans and operating in Vermont, USA since 2014. We specialize in Custom Analog, Digital & Mixed Signal Design and advanced packaging architectures. We have a deep background in Memories and ultra-low power architectures. Our experience covers all technology nodes up to 2nm FINFET. | TA2: Wet chiplets TA3: Biocompatible packaging TA4: Human Factors testing | TA1: Dry Chiplets unique to Biosensing |
| Simon dOelsnitz | Harvard Medical School | simon_doelsnitz@hms.harvard.edu | Boston, MA | Our group specializes in the engineering of prokaryotic transcription factors with custom small molecule specificity. We have engineered TF sensors for pharmaceuticals, steroid hormones, common metabolites, and environmental pollutants. | We are looking for collaborators who can integrate our protein-based sensors into electrochemical chips. Small molecule recognition by our sensors causes them to dissociate from DNA. We need to transduce this binding/unbinding event into a digital signal | TA2: Wet Biosensing Chiplets, TA1: Dry Chiplets unique to Biosensing |
| Sachin Junnarkar | Health Lync LLC | junnarkar@thehealthlync.com | Austin, TX | Wellyfy's research focuses on modular microelectronics and photonics for advanced biosensing in healthcare. Key areas: Mixed-signal chip design and chiplet architectures for low-power, heterogeneous integration and remixable components. Advanced packaging, including biocompatible/hermetic solutions for reliable body interfacing. Silicon photonics via AIM Photonics membership (full SDK/PDK access) for optical interconnects, low-SWaP secure comms, and biosensor integration. EMR integration, AI/ML | Wellyfy seeks teaming partners with expertise in: Biochemical biosensors (e.g., hormones, cytokines, drug levels) Wet chiplet design for body-fluid interfacing Biocompatible/hermetic packaging & integration Low-power, secure wireless/data protocols. Partners should complement our mixed-signal/chiplet design, silicon photonics (AIM SDK access), advanced packaging, EMR platform, patented digital stethoscope, and physician networks for real-world testing/adoption. | TA1: Dry Chiplets unique to Biosensing, TA3: Biocompatible Encapsulation |
| Anthony Flannery | Healthcare | Anthony.Flannery@analog.com | Wilmington, MA | Analog Devices has deep expertise in semiconductor packaging, ultra-low power electronics, high-quality signal chain, and additional areas particularly relevant to TA1. | We would seek to partner with organizations who have compelling expertise in TA2 and TA4 areas. | TA1: Dry Chiplets unique to Biosensing, TA3: Biocompatible Encapsulation |
| John Bell | HedgeFog Research | jbell@hedgefogresearch.com | Los Angeles, CA | Smart contact lens for initial sensing of glucose, lactate, and cortisol. | Secure helth data storage and transmission | TA1: Dry Chiplets unique to Biosensing, TA2: Wet Biosensing Chiplets |
| Christina Seeholzer | HRL | cmseeholzer@hrl.com | Malibu, CA | Heterogeneous integration, chiplet design (RF - sensing and communications) | Partners to address biosensing technical areas | TA1: Dry Chiplets unique to Biosensing |
| Garrison Crouch | HRL Laboratories, LLC | gmcrouch@hrl.com | Malibu, CA | We provide top-tier microelectronic foundry services for federal agencies and companies in the commercial and military sectors, including major defense contractors. Our 10,000-square-foot, ISO 4 clean room and other supporting labs provide comprehensive microelectronics and nanotechnology fabrication capabilities, such as material growth, deposition, structure formation and characterization. These facilities enable world-record component performance and novel nanoscale device structures. | Seeking teaming partners with expertise in biosensing technologies to develop the “wet” chiplets (body interface, biomarker detection, bioanalytical chemistry etc). Additionally looking for collaborators with experience in biocompatible wearable/ingestible packaging design/testing. | TA1: Dry Chiplets unique to Biosensing, TA3: Biocompatible Encapsulation |
| Sufi Zafar Zafar | IBM | szafar@us.ibm.com | Yorktown Heights, NY, NY | IBM Research is focusing on advancing the development of miniaturized, low power, and highly scalable silicon based biosensing technology designed to enable next generation portable health monitoring platforms. IBM leverages its vast expertise in device physics, materials, chemistry and nanofabrication to demonstrate advanced biosensing devices that are transferrable to semiconductor foundries for cost-effective volume production. | We are looking to teaming with researchers in areas such as dry chiplets for biosensing, packaging and clinical testing. | TA2: Wet Biosensing Chiplets |
| Steven Wysmuller | IBM Research | steve.wysmuller@ibm.com | Yorktown Heights, NY | IBM Research is focusing on advancing the development of miniaturized, low‑power, and highly scalable silicon‑based biosensing technology designed to enable next‑generation portable health‑monitoring platforms. IBM leverages its vast expertise in device physics, materials, chemistry, and nanofabrication to demonstrate advanced biosensing devices that are transferrable to semiconductor foundries for cost-effective volume production. | We are looking to team with researchers in areas such as dry chiplets for biosensing, and packaging and clinical testing. | TA2: Wet Biosensing Chiplets, TA3: Biocompatible Encapsulation |
| Abhinav Bhushan | Illinois Institute of Technology | abhushan@iit.edu | chicago, IL | biosensors, chemical sensors, mems, microfluidics, closed loop | team lead | TA2: Wet Biosensing Chiplets, TA3: Biocompatible Encapsulation |
| Heath Hartle | Impli | heath@impli.org | Route de la Corniche 5A, 1066 Epalinges, Switzerland/84 Wood Lane, White City, W12 7RZ, U.K. | Biosensing with electrochemical sensing using aptamer chemistry for targeted, specific sensing to the picogram range. | Clinical validation partners, CROs, Regulatory partners | TA2: Wet Biosensing Chiplets, TA3: Biocompatible Encapsulation |
| Mark Cheng | Indiana University | chengma@iu.edu | 535 W Michigan Street Indianpolis IN 46202, IN | Biosensors, Flexible electronics, Packaging | We are looking for the partners for TA1 | TA3: Biocompatible Encapsulation, TA2: Wet Biosensing Chiplets |
| Muhammad Mujeeb-U-Rahman | Integrated Medical Sensors Inc. | mujeeb@integratedmedicalsensors.com | Irvine, CA | IMS develops electronics for biosensors, including tiny microelectronics such as integrated circuits (chips). We have over 10+ years of experience and multiple patents in this field. | We want partners with chemistry expertise for reliable, stable chemistry for the biomarkers of interest to Delphi program. | TA1: Dry Chiplets unique to Biosensing, TA2: Wet Biosensing Chiplets |
| Gabriel loke | International Fabric Machines | gabriel@internationalfabricmachines.com | Boston, MA | IFM (MIT spin-off) develops modular fiber-based chiplet systems for wearable/ingestible biosensing, spanning 3D-folded programmable chiplets with embedded sensing, computing, communication (ref: “A single-fibre computer enables textile networks and distributed inference”). We also make fibers with ultrathin metal contacts, microfluidics, optical probes (r:“Multifunctional microelectronic fibers enable wireless modulation of gut and brain neural circuits”) that can be chopped into small chiplets. | We seek TA2-4 partners with strong biosensing and/or clinical trial expertise, especially in wet biosensors, surface chemistry/passivation, biocompatible encapsulation, sterilization, regulatory planning, human factors, and clinical studies—to complement our chiplet integration strengths and support full Delphi device translation | TA1: Dry Chiplets unique to Biosensing, TA2: Wet Biosensing Chiplets |
| Angik Sarkar | Ixana | angik@ixana.ai | West Lafayette, IN | Ixana develops ultra-low-power, secure wireless chips. Our core technologies include Wi-R, an E-field based communication technology for wire-like, RF-free continuous health monitoring at sub-mW power, and NIST-compliant Post-Quantum Cryptography (PQC) chiplets. Designed for battery-powered edge devices, our solutions ensure quantum-proof security and up to 20 Mbps data transfer at 100x lower power than Bluetooth, directly enabling advanced real-time biosensing. | We are looking for partners specializing in TA2 (wet biosensing chiplets) and TA3 (biocompatible encapsulation) to integrate our Wi-R and PQC technologies into complete wearables / ingestible. Ideal collaborators include system integrators, microelectronics packaging experts, and clinical researchers (TA4) who can help validate our ultra-low-power, secure communication chiplets within modular, continuous health monitoring platforms for the Delphi program. | TA1: Dry Chiplets unique to Biosensing |
| Zahra Chaudhry | JHU/APL | Zahra.chaudhry@jhuapl.edu | Laurel, MD | JHU/APL has a long history integrating diverse research and development and transitioning technologies to end users. JHU/APL maintains research and engineering expertise in integrated circuits, biomaterials, biomarkers discovery, systems integration, and sensing and response. | JHU/APL has experience as Prime Contractor and team lead for technology integration projects. We seek expertise in microneedles to support sampling, wet sensing of biomarkers, and clinical trial testing. | TA1: Dry Chiplets unique to Biosensing |
| Neelotpala Kumar | Ki | neelotk@utexas.edu | Austin, TX | Ki is spinning out of the ARPA-H CLINAC- BP program at UT Austin. Our team has expertise in RF-based physiological sensing for cuffless Blood Pressure monitoring and electrochemical wet sensing. Ki is building a minimally invasive wearable patch combining continuous physiological and biochemical monitoring in a single device, targeting cytokine detection (IL-6) in ISF for inflammatory and early sepsis monitoring. | Ki leads wet biosensing (TA2) and system integration, with collaborators for encapsulation (TA3). Seeking: TA1 - semiconductor packaging for heterogeneous chiplet integration. Microneedle partner for ISF sample collection and microfluidic delivery. TA4 -clinical/regulatory partner for human factors, trials, and FDA strategy for minimally invasive devices. | TA2: Wet Biosensing Chiplets, TA1: Dry Chiplets unique to Biosensing |
| Osh. Agabi | Koniku Corp | agabi@koniku.com | Hayward, CA | Smell Cyborgs to detect small and large molecules. | clinical trials, deep understanding of biomarkers, experimental design and testing, packing and manufacture. | TA2: Wet Biosensing Chiplets, TA2: Wet Biosensing Chiplets |
| Christopher Stricklan | Kraetonics, LLC. | chris@kraetonics.com | West Melbourne, FL | We are a small business focused on advanced hybrid manufacturing. We have the only tools to design and build for arbitrary shapes placing dielectric and conductive materials at any point in the 3D Space. Our main interests are going to be in the design, manufacturing, and packaging of the sensors. We have been awarded on multiple ARPA-H programs and have successfully led to teams through the process of doing work with ARPA-H. | We are looking for a team that has an interesting use case for medical device sensors that would require unique packaging and design characteristics. | TA1: Dry Chiplets unique to Biosensing, TA3: Biocompatible Encapsulation |
| Margaret Melville | Lasa Health | margaret@lasahealth.com | Boulder, CO | Lasa Health develops digital health tools and clinical research platforms focused on pelvic pain and reproductive health disorders, including endometriosis. Our work centers on patient phenotyping, AI-enabled symptom tracking, digital biomarkers, and integration of wearable and biosensor data to support improved diagnosis, monitoring, and treatment personalization. | We do not develop proprietary wearable hardware. We seek to collaborate with teams building novel biosensors, wearable or ingestible sensing platforms, and bioelectronic devices. Lasa Health can support clinical validation, digital biomarker development, patient recruitment, and data integration, particularly for applications in pelvic pain, reproductive health, and chronic inflammatory conditions. | TA4: Human Factors Testing or Clinical Trial |
| James Rathburn | LCP Medical Technologies, LLC | jrathburn@lcp-medical.com | Brooklyn Park, MN | Our focus is patented high layer count, hermetic Liquid Crystal Polymer circuit technologies with sub-10 micron geometries for direct die attach, embedded dry active chips and passive microelectronics, embedded wet sensor devices, galvanic and solid- state power cells, integrated microfluidics, noble conductors, local wireless and secure RFMW communications, in process functional testing prior to embedding. We can enable the DELPHI ecosystem with our newly deployed MN facility and LCP platform. | We have the LCP manufacturing installed and ready to perform, and would work with device and sensor providers, medical device OEMs, academic and design experts to refine the microelectronic content and functional requirements that integrate seamlessly into our LCP platform and enable a broad range of heterogeneous and customizable sensing, measurement, communication and diagnostic indication outcomes. | TA3: Biocompatible Encapsulation, TA1: Dry Chiplets unique to Biosensing |
| Mike Fantini | Lyten Federal | mike.fantini@lyten.com | San Jose, CA | Lyten is an advanced materials/applications company empowered by 3-D graphene (3DG) enabling extremely sensitive sensing capabilities. It has developed an array-based sensor that combines high sensitivity with the selectivity needed to accurately detect and identify target vapors in real-world environments. The sensor consists of 3DG layers on a circuit measuring frequency responses using impedance spectroscopy, with an analytical technique measuring changes in complex impedance. | Lyten is open to partnering with any organization or company that has an interest in sensing of vapor and organic compounds utilizing low cost methods. | TA1: Dry Chiplets unique to Biosensing, TA2: Wet Biosensing Chiplets |
| Joel Voldman | Massachusetts Institute of Technology | voldman@mit.edu | Cambridge, MA | Microfluidic sample preparation and electronic biomolecular detection. | Binder development. | TA2: Wet Biosensing Chiplets |
| Xiling Shen | MD Anderson, Terasaki Institute | xilings@gmail.com | Los Angeles, CA | We develop various wearable sensors for saliva, sweat, tears , ISF, for clinical and healthy life applications. | We look for academic or industry partners with unique capabilities in chiplet architecture. | TA1: Dry Chiplets unique to Biosensing, TA2: Wet Biosensing Chiplets |
| Natalie Wisniewski | Medical Device Consultancy | natalie.w.science@gmail.com | Hobart, IN | I am an individual with career-long entrepreneurial experience in developing and commercializing multi-analyte, multi-parameter sensors. I deeply understand the technical challenges of sensors on and in the body. I raised over $150M in grant and investor funds for sensor start-ups including Profusa, which is now public. I aim to provide commercial and development leadership for the most innovative sensing technologies in the world and to drive them for the benefit of mankind. | I am looking for extraordinary chemistry capabilities to both strategize and synthesize recognition elements and create associated linker/ containment/transduction approaches. I bring a strong network of capabilities for TA 1, 3 and 4, but I am looking for scalable chemistry capabilities for TA 2. | TA3: Biocompatible Encapsulation, TA1: Dry Chiplets unique to Biosensing |
| Neha Patel | Medtronic | neha.m.patel@medtronic.com | Tempe AZ, AZ | Biophysical and Biochemical sensors and hermetic sealing for implantable and wearable products | Clinical applications and studies for improved health outcomes. | TA3: Biocompatible Encapsulation, TA1: Dry Chiplets unique to Biosensing |
| Anand Muthusamy | Melody FRO | anand@convergentresearch.org | Los Angeles, CA | Focused research organization designing modular biosensors de novo for continuous monitoring. We computationally design conformation-switching binders, opening new scaffolds for challenging targets like cytokines, and tune selectivity, kinetics (regeneration), and stability via directed evolution for rapid targeting. We develop single-channel and cross-reactive array modes with CMOS integration. Open-science model; collaborations with protein design labs, ASIC CROs, and clinical partners. | TA1 partner: medical device chiplet packaging at scale, substrate and interconnect design, ultra-low-power front-end, and secure data transmission. TA3 partner: hermetic encapsulation capability at chiplet scale with option for selective exposure of biosensing surfaces. Solutions must be biocompatible and compatible with protein-functionalized microwell and surface arrays, including membrane and electrode surface chemistries. | TA2: Wet Biosensing Chiplets, TA3: Biocompatible Encapsulation |
| Wen Li | Michigan State University | wenli@msu.edu | East Lansing, MI | Fraunhofer USA Center Midwest (CMW), located at Michigan State University (MSU), specializes in diamond growth and integration into advanced sensing platforms. In collaboration with MSU, CMW has developed key technologies in multichannel electrochemical sensors, microfluidic integration, and flexible/wearable systems. Applications span healthcare, environmental monitoring, and neuroscience, with proven capabilities in scalable diamond and advanced carbon materials for high-performance sensing. | We are seeking potential teaming partners with expertise in advanced integration, packaging, and high-density interconnection technologies. We are also interested in partners with capabilities in human studies and clinical validation, including IRB-approved trials and translational research. | TA2: Wet Biosensing Chiplets, TA3: Biocompatible Encapsulation |
| Jinxing Li | Michigan State Unviersity | jl@msu.edu | East Lansing, MI | Wearable biosensing, biomolecular detection, electrochemical sensing | Chiplet design, data science/AI | TA2: Wet Biosensing Chiplets, TA4: Human Factors Testing or Clinical Trial |
| Norelle Wildburger | Nanost | norelle.wildburger@nanost-inc.com | Gaithersburg, MD | Nanost develops nanobody-enabled microfluidic biosensing systems for rapid, multiplex detection of protein biomarkers from small blood samples. Our platform integrates passive plasma separation, chaotic advection mixing, and fluorescence detection to enable compact, field-deployable diagnostic infrastructure. Current applications include cardiac injury, neurodegeneration, and inflammatory biomarkers in decentralized and austere environments. | Nanost seeks partners with expertise in microelectronics, chip-scale sensor integration, low-power wireless communication, secure data architectures, and biocompatible packaging. Ideal collaborators will help integrate molecular biosensing modules with wearable or implantable systems, enabling continuous monitoring of physiological biomarkers and data integration for predictive health analytics and digital twin models. | TA1: Dry Chiplets unique to Biosensing, TA2: Wet Biosensing Chiplets |
| Prashant Anantharaman | Narf industries llc | prashant.anantharaman@narfindustries.com | San Diego, CA | We work to secure connected medical devices using formal methods and reverse engineering. We focus on designing secure protocols, such as those that build on low-power wireless communication protocols like BLE and NFC, encrypting and authenticating resource-limited embedded systems, modeling threats, and parallel implementations for low latency. | A TA1 prime proposer looking for a dedicated cybersecurity partner. We bring expertise in secure protocol design, encryption for resource-constrained hardware, and medical device security compliance. | TA1: Dry Chiplets unique to Biosensing |
| June Lee, MD, PhD | National Society of Medical Scientists (NSMS) | Dr.JuneLee@nsmsusa.org | Bethesda, MD | NSMS Team S is a clinical powerhouse focusing on deep biological monitoring and trial execution. Our research spans women’s reproductive health, cardiology, immunology, and neurology. We integrate AI healthcare architecture with digital twin clinical trials to model patient responses and optimize study designs. By leveraging Data Coordinating Centers (DCCs), we transition biosensor "chiplets" from prototypes to validated devices through FDA-compliant pragmatic and synthetic-arm trials. | NSMS Team S is a clinical powerhouse focusing on deep biological monitoring and trial execution. Our research spans women’s reproductive health, cardiology, immunology, and neurology. We integrate AI healthcare architecture with digital twin clinical trials to model patient responses and optimize study designs. By leveraging Data Coordinating Centers (DCCs), we transition biosensor "chiplets" from prototypes to validated devices through FDA-compliant pragmatic and synthetic-arm trials. | TA4: Human Factors Testing or Clinical Trial, TA3: Biocompatible Encapsulation |
| Marc Powell | Nautilus Defense | marc@powellinnovative.com | Pawtucket, RI | Nautilus develops advanced textile-integrated electronic systems that seamlessly embed power, data, sensing, and RF capabilities into fabrics. By engineering novel materials and integration methods, Nautilus enables distributed sensor networks, antenna arrays, and electrical architectures within flexible, wearable platforms for continuous physiological monitoring, real-world data collection, and scalable medical sensing applications. | We seek partners with demonstrated expertise in biosensing and biointerfaces, including continuous monitoring of low-concentration biomarkers, anti-fouling and regenerative surface chemistries, and scalable sensing approaches. We also seek capabilities in miniature, hermetic, biocompatible packaging for wet chip-scale systems operating in physiological environments. Our team provides strengths in system integration and custom ASIC development. | TA1: Dry Chiplets unique to Biosensing, TA4: Human Factors Testing or Clinical Trial |
| Khalil Ramadi | New York University | kbr5930@nyu.edu | New York, NY | Ingestible devices, in vivo experimentation, human trials | Scalable manufacturing | TA3: Biocompatible Encapsulation, TA4: Human Factors Testing or Clinical Trial |
| Roger Narayan | North Carolina State University | roger_narayan@ncsu.edu | Raleigh, NC | Our current research focuses on microneedle-based and other minimally invasive biosensing platforms for continuous monitoring of cytokines, drug levels, metabolites, and related biomarkers. We combine electrochemical sensing, additive manufacturing, biomaterials, surface functionalization, and device integration to develop wearable point-of-care systems with clinically relevant performance. | We are seeking teaming partners with strong capabilities in chiplet packaging/interconnects, ultra-low-power electronics, secure wireless communication, preclinical/clinical translation, and regulatory strategy. | TA2: Wet Biosensing Chiplets, TA3: Biocompatible Encapsulation |
| Sundar Nadarajan | Nova Biosensors | Sundar@novabiosensors.com | West Chester, PA | Continuous, discrete and single use biosensor design, fabrication and scaleup | Dry chips and human factor testing | TA2: Wet Biosensing Chiplets, TA3: Biocompatible Encapsulation |
| Paola Bardettib | NYU | paola.bardetti@gmail.com | New York City, NY | Our research is focused on developing high sensitive FET-based biosensors for developing rapid-tests. | We are looking to teaming with partners for testing in humans and knowledge on clinical trials. | TA2: Wet Biosensing Chiplets, TA1: Dry Chiplets unique to Biosensing |
| Larry Cheng | Oregon State University | chengli@oregonstate.edu | Corvallis, OR | We focus on biosensing technology development, including novel synthetic biosensing receptors, functional and packaging materials, microfluidics, electrochemical and optical sensing methodologies, sensing IC design with electronic system integration and wearable sensor modules. We have demonstrated wearable detection for sweat steroid hormones and are currently expanding the capabilities for continuous detection. | We are looking for organizations for human factors testing and clinical trials. | TA2: Wet Biosensing Chiplets, TA1: Dry Chiplets unique to Biosensing |
| Nader Shokair | OVAI | nadershokair@gmail.com | Santa Monica, CA | Translational research in women's health endocrinology with clinical deployment infrastructure across 800+ OB/GYN locations nationally. Expertise in biomarker validation, clinical trial design, and patient retention strategies for perimenopausal populations. Provisional IP on continuous non-invasive hormone monitoring using novel sensing platforms. Strong clinical partnerships with academic medical centers and multi-state hospital networks. | Clinicians, endocrinological researchers and specialists, along with electrical engineering SMEs in, biosensing, telemetry, and wearable electronics. Seeking technical partners in: (1) Ultra-low-power microelectronics and secure wireless communication for continuous biosensing, (2) skin patch design (Maybe: electrochemical transduction). Ideal collaborators have experience with ARPA-H/DARPA programs, rapid prototyping capabilities, and scalable manufacturing expertise. | TA2: Wet Biosensing Chiplets, TA4: Human Factors Testing or Clinical Trial |
| Thomas Berti | Planned System International | Tberti@plan-sys.com | Arlington, VA | PSI brings a premier Federal IT and Healthcare presence with 35+ years of experience. As a current ARPA-H performer, we provide the ready-to-scale capability. We also specialize in commercializing ARPA-H products, securing data with Post-Quantum Cryptography, and using our customized EHR platform to harmonize health information wirelessly. PSI is the ideal partner to navigate federal regulations and transition prototypes into the market. | We are seeking partners to fill critical hardware gaps in TA1 (Dry Chiplets) and TA2 (Wet Chiplets). We need innovators with breakthrough low-power microelectronics or novel biochemical sensing hardware who lack a clear path to clinical adoption. PSI fills the last mile by providing the Federal IT and Healthcare expertise needed to integrate, secure, and commercialize these prototypes, successfully transitioning lab-scale sensors into the broader ARPA-H ecosystem. | TA4: Human Factors Testing or Clinical Trial, TA1: Dry Chiplets unique to Biosensing |
| Amy Beckley | Proov | amy@mfbfertility.com | Boulder, CO | We currently monitor menstrual cycle hormones daily in urine using a lateral flow and in-app imaging technology. Along side this DTC solution, we have developed a clinical-facing novel wet biosensor that can continuously monitor any analyze (not just hormones) in any fluid. Our biosensor does not require aptamers. This technology has the ability to enter the market faster and is significantly lower cost than aptamer-based biosensors, which still face significant technical challenges. | We are looking to partner with companies with expertise in TA1, TA3, and TA4 that wants to help us commercialize a system with a potential to enter the market 3X faster than aptamer-based systems. | TA2: Wet Biosensing Chiplets |
| Ryan Callahan | Prova Health | ryan.callahan@provahealth.com | Miami, FL | We have experience specifically in diagnostic technology, supporting a variety of organizations (academic labs, start-ups, and enterprises) to successfully commercialize innovative products and services. We are familiar with both core scientific challenges in improving validity of wearable data as well as health system realities that have limited the impact of the previous generation of technologies. We previously worked with a similar effort led by a different ARPA-like organization. | We are looking to partner with teams who have a strong technical and clinical background and who want to de-risk the scaled adoption of their technology into the healthcare system. We can help with reimbursement strategy, ideal customer profiles, go-to-market plans, sales forecasting, strategic exit options, competitive analysis, clinical workflow, simulation-based feasibility testing, and adjacent activities. | TA4: Human Factors Testing or Clinical Trial |
| Wenzhuo Wu | Prudue University | wenzhuowu@purdue.edu | West Lafayette, Indiana, IN | Purdue delivers across-the-stack innovations in advanced 2D semiconductor-based sensors, algorithm-hardware co-design, CMOS+X integration, and 3D heterogeneous packaging for scalable, high-performance health monitoring. Capabilities span energy-efficient chiplet architectures, wearable chemical/biological sensors with catalytic functionalization and digital twin modeling, semiconductor packaging reliability, and scientific machine learning with uncertainty quantification. | We seek partners with: (1) biochemistry/molecular biology experts in biorecognition elements (aptamers, antibodies, synthetic receptors) for multiplexed detection of hormones, immune markers, and therapeutic drug levels; (2) clinical institutions with IRB infrastructure, wearable/ingestible device trial management, and FDA regulatory experience; (3) medical device or health technology industry partner for commercialization and manufacturing scale-up. | TA2: Wet Biosensing Chiplets, TA1: Dry Chiplets unique to Biosensing |
| Polona Safaric Tepes, PhD | PSSP Technologies | dr.safaric@gmail.com | NYC / Oyster Bay, NY | Continuous biosensing for real-time hormone monitoring in non-invasive biofluids. Selective molecular recognition chemistry for steroid hormones at picomolar concentrations, electrochemical transduction, multi-analyte detection in complex matrices, clinician-curated clinical decision indices for perimenopause navigation. Focus: perimenopause, integrated bioanalytical chemistry, sensor engineering, clinical endocrinology, and patient-centered design. | Collaborators in low-power wireless systems, biocompatible packaging, and advanced biosensing platforms for continuous monitoring applications. Ideal partners bring complementary technical depth, rapid iteration capabilities, and experience navigating federal R&D programs. Open to academic institutions, commercial entities, or hybrid teams with demonstrated ability to translate research to deployable prototypes | TA2: Wet Biosensing Chiplets, TA4: Human Factors Testing or Clinical Trial |
| Shreyas Sen | Purdue University | shreyas.sen@gmail.com | West Lafayette, IN | Lowest power bioelectronics | Complimentary skillset | TA1: Dry Chiplets unique to Biosensing, TA2: Wet Biosensing Chiplets |
| Shubhra Bansal | Purdue University | bansal91@purdue.edu | USA, IN | Chiplet heterogeneous integration | I am looking to contribute 3D-HI capability to a team’s biosensors concepts | TA1: Dry Chiplets unique to Biosensing, TA3: Biocompatible Encapsulation |
| Rahim Rahimi | Purdue University | rrahimi@purdue.edu | West Lafayette, IN | Our lab develops next-generation ingestible and wearable sensing platforms for real-time monitoring of human health. We specialize in smart capsule technologies capable of targeted delivery, localized sensing, and biological sampling throughout the GI tract. We integrate flexible electronics, electrochemical biosensors, and advanced microelectronics packaging to create low-power, wireless systems for continuous monitoring of different biomarkers. | We seek partners to accelerate clinical translation of our technologies, including expertise in FDA regulatory strategy, clinical trial design, and first-in-human studies. We welcome collaborators in low-power electronics, and ASIC/tape-out. | TA2: Wet Biosensing Chiplets, TA1: Dry Chiplets unique to Biosensing, TA3: Biocompatible Encapsulation |
| Lauren Mount, MD | QuantaBiologics | lem@quantabiologics.com | New York, NY | Real-time physiological analytics, multi-analyte wearable biosensing, temporal persistence and digital twin modeling, predictive metabolic biomarkers, clinical and microgravity validation | Sensor hardware integration, low-SWaP biosensor packaging, biocompatible encapsulation | TA2: Wet Biosensing Chiplets, TA4: Human Factors Testing or Clinical Trial |
| Natalie Cookson | Quantitative BioSciences, Inc. | natalie.cookson@qbisci.com | San Diego, CA | We are a small business specializing in biosensor development. We have a VHH (single-domain antibody) library that we can screen to rapidly find sensing elements to biological targets including cytokines, hormones, drugs, etc. | We are looking to serve as a subcontractor to produce sensing elements that can be integrated into a larger project. | TA2: Wet Biosensing Chiplets |
| Shilpi Gupta | Qyn Labs, Inc | shilpi@qynlabs.com | Cambridge, MA, USA, MA | Qyn Labs develops modular aptamer-based sensing platforms for continuous multi-hormone monitoring, targeting femtomolar-to-picomolar detection of estradiol, testosterone, progesterone, and cortisol. Our structure-switching aptamer chemistry is transduction- and matrix-agnostic, built for rapid biomarker reconfiguration and chiplet-compatible wearable deployment. Validated in serum; academic partnership at NC State; active clinical and diagnostics industry collaborations. | Qyn Labs seeks partners with expertise in ultra-low-power chiplet design, mixed-signal circuit integration, and miniaturized secure wireless communication for biosensing applications — ideally with demonstrated heterogeneous chiplet integration experience. Biocompatible encapsulation is addressed through existing partnerships. We welcome conversations with clinical research organizations and regulatory strategists experienced in FDA pathways for novel diagnostics. | TA2: Wet Biosensing Chiplets, TA3: Biocompatible Encapsulation |
| Ben Bulloch | RetinaTek Inc | ben@retinatek.com | Rockville, MD | RetinaTek develops eye-tracking-based neurofunctional measures for rapid, objective assessment of cognitive readiness, recovery, and impairment. Our current work combines structured visual stimuli, synchronized eye movements, pupillometry, and reaction-time data to generate validated functional metrics. We are extending this foundation toward low-burden passive and semi-passive monitoring using head-worn displays and contextual visual cueing. | We seek prime teams building non-invasive wearable sensing platforms who want to add a neurofunctional layer to continuous biomarker monitoring. Ideal partners bring hardware, biosensing, integration, and data infrastructure. RetinaTek brings validated structured eye-tracking tasks plus a roadmap for HUD-delivered passive/semi-passive microstimuli that may enable continuous estimation of readiness, recovery, stress, or decline. | TA4: Human Factors Testing or Clinical Trial |
| Chong Xie | Rice University | chongxie@rice.edu | Houston, TX | Neural electrodes, ultraflexible and large-scale. | Teams who need a fabrication and/or packaging partner. | TA3: Biocompatible Encapsulation, TA2: Wet Biosensing Chiplets |
| Juliane Sempionatto | Rice University | jsemp@rice.edu | houston, TX | Wearable biosensors | TA3 and TA4 | TA1: Dry Chiplets unique to Biosensing, TA2: Wet Biosensing Chiplets |
| Yong Lin Kong | Rice University | kong@rice.edu | Houston, TX | Our group develops advanced manufacturing capable of heterogeneous integration of functional materials and chiplets for bioelectronics. Our work spans wireless ingestible devices, soft bioelectronics, and multimaterial integration (e.g., Nature Electronics, Nature Communications, Science Advances). The PI is an inventor of ingestible gastric resident electronics and leads interdisciplinary projects on bioelectronics, such as ingestible systems for longitudinal sensing. | We seek collaborators in ASIC chiplet design for ultra-low-power biosensing, post-quantum secure communications, and sensor surface chemistry for continuous detection of low-concentration analytes. | TA3: Biocompatible Encapsulation, TA2: Wet Biosensing Chiplets |
| Kaiyuan Yang | Rice University | kyang@rice.edu | Houston, TX | Low-power digital, mixed-signal, power IC, bioelectronics, hardware security, intelligent sensor interface with embedded computation. We have recently demonstrated one of the first 2-factor authentication system for secure communication to mm-scale biomedical implants. | Contact me if you need capabilities with low-power hardware-enabled security and precise 6-DoF localization solutions for ingestible devices. | TA1: Dry Chiplets unique to Biosensing, TA2: Wet Biosensing Chiplets |
| Scott Hiatt | Ripple | scott@rppl.com | Salt Lake City, UT | We design and assemble hermetic class 3 research implants for chronic biosensing in our Class 7 cleanroom, we have bio amplification and stimulation ASICs , wireless RF powering and telemetry for implantables, a platform implant system that can be incorporate various sensors. We also have systems to allow benchtop prototyping and testing with percutaneous versions of the sensor systems. We are an ISO 13485 certified medical device designer and manufacturer. | Teams with novel sensors, teams needing a manufacturing partner specializing in low volume human-grade R&D implants | TA1: Dry Chiplets unique to Biosensing, TA3: Biocompatible Encapsulation |
| Krittika Goyal | RIT | krgmet@rit.edu | Rochester, New York, United States, NY | Our research focuses on understanding the skin–electrode interface in wearable devices, including bioimpedance and biopotential sensing. We develop smart textile-based electrodes and wearable systems for continuous health monitoring, targeting respiratory, cardiovascular, and thermal metrics. Our work integrates materials, device design, and signal analysis for reliable, long-term, non-invasive sensing. | We seek teaming partners with complementary expertise in smart textiles, advanced materials, flexible/printed electronics, and signal processing. Ideal collaborators include those with capabilities in textile integration, scalable manufacturing, clinical validation, and field deployment for wearable health monitoring systems in real-world and defense environments. | TA1: Dry Chiplets unique to Biosensing, TA2: Wet Biosensing Chiplets |
| MD Ahasan Habib | Rochester Institute of Technology | mahmet@rit.edu | Rochester, NY | Our research focuses on AI-enabled biomanufacturing, multimaterial 3D bioprinting, and biohybrid systems for disease modeling and health monitoring. We develop MRI-informed tissue phantoms with tunable mechanics, integrated sensing, and robotic fabrication. In alignment with ARPA-H DELPHI, we advance modular biosensing platforms and embedded sensing architectures to enable continuous, real-time monitoring of biological signals for early diagnosis and personalized therapy | We seek multidisciplinary partners with expertise in biosensing, AI/ML, embedded systems, and clinical translation. Ideal collaborators include groups working on wearable or implantable sensors, signal processing, and human-subject validation. We value partners with capabilities in scalable manufacturing, regulatory pathways, and healthcare deployment to accelerate translation of sensing-enabled biomanufactured platforms. | TA2: Wet Biosensing Chiplets, TA1: Dry Chiplets unique to Biosensing |
| Simiao Niu | Rutgers, the State University of New Jersey | simiao.niu@rutgers.edu | Piscataway, NJ | Ultralow power analog frontend for biosensors | N/A | TA1: Dry Chiplets unique to Biosensing, TA2: Wet Biosensing Chiplets |
| Erika Tyburski | Sanguina, INC | erika.tyburski@sanguina.com | Peachtree Corners, GA | Sanguina is a digital health company focused on using a smartphone application for image and video analysis of fingernail beds for blood-based biomarkers including anemia and circulation testing and tracking. The platform is completely non-invasive and equipment-free apart from using a compatible smartphone. This allows our company to focus on patients anywhere in the world, with relatively low barriers to use. Recently, we have focused on use by patients with chronic & rare disease. | We are seeking teaming partners with experience in remote patient monitoring payment pathways and partners with experience in designing cost-analysis studies. There are ways to use our technology to predict medical events/outcomes, and we seek to learn how private and public insurance providers could cover and support remote patient monitoring with appropriate ROIs characterized. | TA1: Dry Chiplets unique to Biosensing, TA4: Human Factors Testing or Clinical Trial |
| Matt Sigmund | SIA/LBG | Msigmund@lathambiopharm.com | Elkridge, MD | Sia/LBG provides full-spectrum support for federal funding, specializing in proposal development and post-award execution. Our subject matter experts in digital health bring deep domain knowledge in areas like health IT, AI-driven diagnostics, and data interoperability. We craft compliant, compelling proposals tailored to funder priorities and guide post-award reporting, stakeholder engagement, and program delivery to ensure lasting success. | SIA/LBG is seeking to partner with organizations developing innovative, breakthrough technologies with the potential to satisfy program requirements and that are interested in engaging an experienced partner to enhance proposal development and ensure disciplined, compliant post-award program execution. | TA4: Human Factors Testing or Clinical Trial |
| Kyle Preston | SiPhox Health | kyle.preston@siphox.com | Burlington, MA | SiPhox Health has developed silicon photonics chiplets for evanescent field biosensing, enabling label-free, multiplexed detection of proteins and hormones. Our current platform performs at-home blood testing using a disposable photonic chip, and we are pursuing FDA clearance for a thyroid hormone panel. For Delphi, we will further miniaturize our reader hardware onto a chiplet (TA1) and adapt our multiplexed sensor chip into a subdermal probe for continuous wearable monitoring (TA2). | We bring TA1/TA2 expertise with photonic chiplets for optical signal transduction and a multiplexed biosensing platform on path to FDA clearance. We seek partners for TA1: electronics miniaturization; TA2: non-antibody capture molecules (aptamers, peptides, MIPs) to expand our analyte menu; TA3: biocompatible hermetic encapsulation for subdermal devices; TA4: clinical trial experience and FDA regulatory strategy for semi-invasive wearables. | TA2: Wet Biosensing Chiplets, TA1: Dry Chiplets unique to Biosensing |
| Sarat Gundavarapu | SiPhox Health | sarat@siphox.com | Boston, MA | We are developing at-home blood diagnostics platform for multiplexed biomarker sensing using silicon photonic chips | We are looking for partners with expertise in TA2-4. SiPhox has strong expertise in TA1 and substantial expertise in TA2 | TA1: Dry Chiplets unique to Biosensing, TA2: Wet Biosensing Chiplets |
| Keith Carron | SKM Instruments | keith.carron@skminst.com | Laramie, WY | Wearable optical sensors | Biomarker sensing expertise | TA2: Wet Biosensing Chiplets, TA1: Dry Chiplets unique to Biosensing, TA3: Biocompatible Encapsulation, TA4: Human Factors Testing or Clinical Trial |
| J-C Chiao | Southern Methodist University | jchiao@smu.edu | Dallas, TX | Noninvasive radio-frequency probing of tissues (hydration, glucose, abnormal tissues). Multiplexed point-of-care microfluidic sensors of biomarkers. | ASIC designs, RFIC designs and manufacturing, antibody development, human trials | TA1: Dry Chiplets unique to Biosensing, TA2: Wet Biosensing Chiplets |
| Sheng Xu | Stanford University | shengxu@stanford.edu | Palo Alto, CA | Wearables for deep tissue sensing. Integrating biosensors with chips of high density pins. | chip designers | TA1: Dry Chiplets unique to Biosensing, TA2: Wet Biosensing Chiplets |
| Eyal Metzl-Raz | Stanford University | eyalmetzlraz@gmail.com | Stanford, CA | Building reusable ultra-sensitive sensors | Looking for partners in TA1 and TA4 | TA2: Wet Biosensing Chiplets, TA3: Biocompatible Encapsulation |
| Constantine Sideris | Stanford University | sideris@stanford.edu | Stanford, CA | biomedical devices, bioelectronics, analog/mixed-signal integrated circuits, wearable and ingestible devices, implantable devices | Packaging, encapsulation, industry partners | TA1: Dry Chiplets unique to Biosensing |
| Yixian Qin | State University of New York at Stony Brook | yi-xian.qin@stonybrook.edu | Stony Brook, NY | Stony Brook University has a highly convergent research ecosystem that integrates engineering, biology, medicine, and data science, directly aligning with ARPA-H priorities. Its strengths lie in multiscale biomedical systems, translational engineering, and AI-enabled health innovation. The core research strengths include the integration of engineering and medicine to develop diagnostics, therapeutics, and medical devices. | Key partnership opportunities include collaboration with medical device and wearable technology companies and universities with labs to co-develop next-generation sensing and imaging platforms, healthcare providers and hospital systems to enable clinical validation, longitudinal data collection, and deployment in diverse patient populations, and AI and data science organizations to support scalable, real-time multiscale modeling and predictive analytics. | TA2: Wet Biosensing Chiplets, TA1: Dry Chiplets unique to Biosensing |
| Achim Harzheim | Stealth Startup | aharzheim16@gmail.com | London, United Kingdom | We have developed a platform for sensing arbitrary biomarkers using proteins and signaling cascades which enables sensing of low concentration biomarkers. We have tested multiple targets and shown the general use as a continuous measuring device is feasible. | We haven't spend the time on developing the electronics to the point where we can integrate them into a chiplet. So we are looking for help with chiplet design and packaging integration. | TA2: Wet Biosensing Chiplets |
| Pamela Abshire | Stony Brook University | pamela.abshire@stonybrook.edu | Stony Brook, NY, NY | We have two decades of experience in developing lab-on-CMOS circuits for biointerfaces, including potential, capacitance, optical, and biochemical sensing modalities. Most of these have been developed for cell culture systems, some for dry and macro interfaces. We have also developed techniques for encapsulation so that we can test our devices. | dry chiplets for power management and comms, novel approaches for encapsulation, human trials | TA2: Wet Biosensing Chiplets, TA3: Biocompatible Encapsulation |
| Yayun Du | SYMBIO-X Lab at Vanderbilt University | yayun.du@vanderbilt.edu | Nashville, TN | We develop multimodal wearable and biointegrated biosensing systems for continuous health monitoring. Our work integrates ultra-low-power circuit design, sensor front-end electronics, wireless firmware, electrochemical biosensing (pH, lactate, glucose), and multimodal physiological sensing (EEG, ECG, SCG, PCG, IMU) to translate emerging chips into deployable medical devices. Our systems have been validated in ~500 participants across five countries through collaborations with nine hospitals. | We seek collaborators in chiplet/ASIC design, ultra-low-power electronics, advanced materials and biocompatible packaging, and bioanalytical chemistry for hormone and inflammatory biomarker sensing. Our lab specializes in integrating emerging chips into wearable biosensor systems through circuit design, firmware, wireless connectivity, and human validation to translate new biosensing technologies into deployable medical devices. | TA4: Human Factors Testing or Clinical Trial, TA2: Wet Biosensing Chiplets, TA3: Biocompatible Encapsulation |
| Amy Duwel | Systems & Technology Research | amy.duwel@str.us | Woburn, MA and Arlington, VA, MA | STR offers a multidisciplinary engineering team with expertise across software, hardware, signal processing, and cyber domains. With strengths in early stage development through low-volume production, we collaborate widely with academic researchers, startups, and industry to ensure that advanced technology solutions reach end users. We are a mission-driven, employee-owned organization, committed to solving important national problems by developing and rapidly transitioning advanced technology. | STR would like to support teammates with novel biosensors who need support across any or all of data security, system engineering, low-power electronics and comms, mechanical integration, and prototyping. | TA1: Dry Chiplets unique to Biosensing, TA2: Wet Biosensing Chiplets |
| Michael Weisend | Teledyne Scientific and Imaging | michael.weisend@teledyne.com | Research Triangle Park, NC | Neuroimaging, Neuromodulation, AI/ML, Autonomy | We seek partners with microelectronics and encapsulation expertise as well as potential partners for human subjects trials. | TA4: Human Factors Testing or Clinical Trial, TA1: Dry Chiplets unique to Biosensing |
| Rahul Saini | Teliatry Inc. | rahul@teliatry.com | Richardson, TX | Teliatry Inc. develops ultra‑miniaturized, biocompatible implantable and injectable bioelectronic systems designed for chronic use and continuous physiological monitoring. Our research spans hermetic encapsulation, selective exposure interfaces, and long‑term materials stability for micro‑scale implants, coupled with low power telemetry and app-enabled continuous data capture. We bring deep experience translating miniature implants into scalable, regulatory-ready platforms. | Teliatry seeks teaming partners developing biosensing chiplets, molecular recognition technologies, or system‑level wearable/ingestible platforms that require miniature, biocompatible, long‑term implantable or injectable form factors. We value collaborators focused on continuous monitoring, low‑power architectures, and scalable manufacturing, where Teliatry can contribute expertise in hermetic encapsulation, chronic implant reliability, and regulatory‑ready integration as a sub‑performer. | TA3: Biocompatible Encapsulation, TA1: Dry Chiplets unique to Biosensing |
| Caroline DeBerry | Tenagrity Solutions | caroline@tenagrity-solutions.com | San Jose, CA | Kardiogenics is developing a unified, end-to-end platform that restores the full "afferent limb" of healthcare by combining continuous multimodal physiological sensing (ECG, PPG, SpO, respiration, temperature, motion, and cuffless BP) with real-time AI-driven triage, evdience-baked alerts, and seamless clinical response across hospital, home, and battlefield settings. At the core is CARDINAL AI, which generates evidence-baked alerts with full physiological context, powered by reasoning layer.... | a MIT spinout Startup Continuity Technology who specializes in Molecular sensing of Biomarkers that predicts decompensation. | TA4: Human Factors Testing or Clinical Trial |
| Mehmet Dokmeci | Terasaki Institute for Biomedical Innovation | mdokmeci@terasaki.org | Los Angeles, CA, CA | The current focus areas include wearable sensors, contact lens sensors, vascularized organs on a chip platform, biomaterials for wound healing. | We are looking for chiplet designers. | TA3: Biocompatible Encapsulation, TA2: Wet Biosensing Chiplets |
| Gerard Cote | Texas A&M University/TEES | gcote@tamu.edu | College Station, TX | Texas A&M University/TEES is a land, sea, and space grant tier 1 research-intensive university. We have capabilities in all four technical areas of chiplet design, development, and testing. Within Engineering the Center for Remote Health Technologies and Systems and the Optical Biosensing Lab we develop breakthrough biomedical technologies using stakeholder engagement to advance diagnostic, monitoring, and human performance hand-held, injectable and wearable systems. | Working across the university system, engineering, and centers we can design, develop, and test high performing hand-held and wearable chiplet systems and bring them to technology readiness levels (TRL) of 4-5 beyond the typical 1-2 for academic institutional labs. Our needs include teaming with industrial partners that can advance our prototypes past these TRL levels to full commercialization of devices that empower the healthcare provider and patient toward better health and wellness. | TA2: Wet Biosensing Chiplets, TA3: Biocompatible Encapsulation |
| Philipp Gutruf | The University of Arizona | pgutruf@arizona.edu | Tucson, AZ | Wearable chronic biosymbiotic electronics, wireless power transfer and skin gas sensing | Electrochemical Sensors, ASIC design | TA1: Dry Chiplets unique to Biosensing, TA3: Biocompatible Encapsulation |
| Yaoyao Jia | The University of Texas at Austin | yjia@austin.utexas.edu | Austin, TX | Low power integrated circuit design; Inductive, ultrasonic, and thermoelectric energy harvesting system development; Implantable and wearable biomedical Devices; Miniature neural Iinterface implants. | Looking for partners who work on biomedical device packaging and coating. | TA1: Dry Chiplets unique to Biosensing, TA1: Dry Chiplets unique to Biosensing |
| Fangzhou Xia | The University of Texas at Austin | fangzhou.xia@austin.utexas.edu | Austin, TX | UT Austin is equiped with the Texas Institute of Electronics for advanced semiconductor packaging. Our team has extensive experience in electronics packaging, ingestible electronics platform technology, magnetic navigation deployment, biosensors, chiplet design | Medical experts for clinical application identification, biomarkers, clinical trials. | TA1: Dry Chiplets unique to Biosensing, TA3: Biocompatible Encapsulation |
| Shalini Prasad | The University of Texas at Dallas | shalini.prasad@utdallas.edu | Dallas, TX | Research focuses on biointegrated micro/nano technologies, wearable and point‑of‑care sensors, and data‑driven health analytics. Core areas include noninvasive biomarker sensing, closed‑loop monitoring, AI‑enabled decision support, | low‑cost manufacturing and supply chain; regulatory/quality/reimbursement expertise | TA2: Wet Biosensing Chiplets, TA4: Human Factors Testing or Clinical Trial |
| Mark Vreeke | TransAtlantic Science | mark.vreeke@transatlanticscience.com | Irvine CA, Houston TX, Boston, MA, TX | TAS has experience developing and scaling biosensors. Team members' innovations have driven the production of over 1B sensors | We are looking for partners who can provide the electronics and the digital interfaces that enable the patient to interact with the biosensor readings. | TA2: Wet Biosensing Chiplets, TA3: Biocompatible Encapsulation |
| Roger Tang | Triple Ring Technologies | rtang@tripleringtech.com | Newark, CA | Triple Ring Technologies is a leading partner in developing science-driven products in medtech and life sciences. Our interdisciplinary team (30% PhDs) excels in advancing technologies to FDA approval while working with academic and commercial partners. We offer capabilities in device and system integration, project management, hardware/software development, and assay development. Relevant experience in swallowable technologies, microneedles, and miniaturized sensors. ISO 13485 certified. | We partner with innovators to solve tough problems and create new businesses. From concept to FDA submission, commercialization, and the clinic, we handle technology development and design, as well as complex system integration. We can manage TA 4, support TAs 1-3, and/or act as Team Integrator if appropriate. We are looking for teaming partners that could use our collaborative assistance. We have been a prime, subcontractor, multiparty team member, or vendor on previous proposals and awards. | TA4: Human Factors Testing or Clinical Trial |
| Olurotimi Bolonduro | Triton Systems | Obolonduro@tritonsys.com | Chelmsford, MA | Triton Systems focuses on transitioning early-stage research into functional prototypes for use by early adopters. We have a history of developing novel diagnostic tools and monitoring sensors in the medical field, and regularly team with OEMs to transition the technology. In tandem with our partners, we are experienced with human factors assessment, military standard testing, regulatory strategy, biocompatibility evaluation, biosensor design and validation, and data analytics. | We are looking for partners to support TA1, specifically the manufacturing and packaging of the modular "Interconnect Solutions" and power management. We are also interested in teaming partners to support human clinical trials associated with TA4. | TA4: Human Factors Testing or Clinical Trial, TA3: Biocompatible Encapsulation |
| James Gooch | TTP, plc | james.gooch@ttp.com | Cambridge, UK | The Wearables & Implantables team at TTP supports the end-to-end development of next generation integrated biosensors, from concept to commercialisation (https://www.ttp.com/industries/biosensor-device-development). Our work spans both ‘wet’ & ‘dry’ systems, from sensor development, functionalisation, and testing, to ultra-low-power electronics & comms, encapsulation, and firmware. We operate under ISO 13485-certified development and manufacturing processes to enable clinical-ready products. | We are looking to partner with teams that have complementary depth in chiplet architectures, novel sensing technologies, or strong clinical insight into specific biomarkers and use cases. We work best with collaborators who value scalability, and a clear path to clinical and commercial impact. If you are seeking a partner to help translate concepts into integrated, manufacturable systems, please reach out. | TA2: Wet Biosensing Chiplets, TA1: Dry Chiplets unique to Biosensing, TA3: Biocompatible Encapsulation, TA4: Human Factors Testing or Clinical Trial |
| Sameer Sonkusale | Tufts University | sameer.sonkusale@tufts.edu | Boston, MA | Ingestible biosensors, Microelectronics, Microbiome, | Human Factors Testing and Clinical Trial, Chiplet integration | TA2: Wet Biosensing Chiplets, TA1: Dry Chiplets unique to Biosensing |
| Katia Canepa Vega | UC Davis | kvega@ucdavis.edu | Davis, CA | Using a women-centered approach, we design biosensors integrated into cosmetic and wearables, including nail polish, lip products, jewelry, and accessories. We embed colorimetric and electrochemical biosensors to detect chemical signals from body fluids (e.g., saliva, sweat, urine) and environmental exposures. Our work combines fabrication, material processing, interaction design, AI, and app development to enable continuous, on-body monitoring with attention to wearability and human factors. | We seek collaborators with expertise in biosensor characterization (e.g., sensitivity, selectivity, stability, calibration) to support integration into our wearable systems and software platforms. We also seek clinical partners with expertise in clinical trial design and evaluation for validation in relevant populations. In addition, we seek industry partners to support scalability and manufacturing, including engineering of low-power sensing and communication chiplets. | TA4: Human Factors Testing or Clinical Trial, TA2: Wet Biosensing Chiplets |
| Drew Hall | UCSD | drewhall@ucsd.edu | La Jolla, CA | Led by Prof. Drew Hall, UC San Diego’s BioEE Lab brings deep expertise in biosensing, spanning electrochemical and magnetic sensors, wearable ExG interfaces, and low-power bioelectronics. Relevant prior work includes a wearable fentanyl sensor, a wearable cortisol stress patch, and BioMote—a sub-1 µW injectable sensor with wireless power/telemetry for continuous analyte monitoring—demonstrating end-to-end capability in wearable and injectable sensing. | Packaging, chiplet integration | TA1: Dry Chiplets unique to Biosensing, TA2: Wet Biosensing Chiplets |
| Patrick Mercier | UCSD Center for Wearable Sensors | pmercier@ucsd.edu | San Diego, CA, CA | The UC San Diego Center for Wearable Sensors has pioneered many different types of physiochemical sensors for measurement in sweat, ISF, tears, urine, within the GI tract, and beyond. We have expertise in miniaturized electronics, low-power telemetry, energy harvesting, packaging/encapsulation, and more. We've already developed full-platform ingestible sensors with in-vivo testing complete, as an example, and can do sensing of metabolites, hormones, electrolytes, and more. | Open to ideas | TA1: Dry Chiplets unique to Biosensing, TA2: Wet Biosensing Chiplets |
| Klearchos Papas | University of Arizona | kkpapas@surgery.arizona.edu | Tucson, AZ | Implantable, fully retrievable microchambers designed with synthetic biomaterials that integrate with the host, mitigate foreign body responses and form a hospitable environment that can house and protect electronics, sensors, readers, or cells in the human body. | Partners with capabilities and assets in TA1 and TA2 | TA3: Biocompatible Encapsulation |
| Hyoyoung Jeong | University of California, Davis | ecejeong@ucdavis.edu | Davis, CA | Our research focuses on developing clinical-grade wearable and implantable bioelectronics for continuous monitoring and closed-loop therapeutics. We specialize in skin-interfaced e-tattoos, wireless sensing systems, and multimodal physiological signal integration, with applications in neurological disorders, maternal-fetal health, and personalized digital health platforms. | We seek multidisciplinary partners with expertise in chiplet design, advanced packaging, low-power ICs, AI/ML for biosignal analysis, and secure data systems. Clinical collaborators and industry partners with capabilities in scalable manufacturing and translation to real-world healthcare settings are highly desired. | TA4: Human Factors Testing or Clinical Trial, TA2: Wet Biosensing Chiplets |
| Erkin Seker | University of California, Davis | eseker@ucdavis.edu | Davis, CA | We develop (i) microfabrication-compatible nanoporous metal-based working electrodes for biofouling-resilient molecular sensing and electrophysiological recordings, and (ii) microphysiological models of neuroinflammation and neurodegeneration. | We are looking for partners that (i) design probes (e.g., aptamers) for continuous molecular capture/release to functionalize our electrode structures, (ii) engineer implantable microelectronics for system-level integration of our electrodes, and (iii) eventually test the sensors in clinically-relevant testbeds. | TA2: Wet Biosensing Chiplets |
| Sazadur Rahman | University of Central Florida | mohammad.rahman@ucf.edu | Orlando, FL | Our current research focus on multi-party computation based secure chiplet communication, secure interposer and packaging design, AI based chiplet placement, and thermal management. | We are interested to team up with system in package designers, chiplet designers so that we can team up and our team can contribute into ensuring assurance. | TA1: Dry Chiplets unique to Biosensing |
| Swaminathan Rajaraman | University of Central Florida | swaminathan.rajaraman@ucf.edu | Orlando, FL | Micro/nanofabrication technologies development; microelectrode arrays; 3D printing; MEMS; Wearable sensors; in vitro sensors; organs on a chip; hermetic packages; impedance electrodes; wireless telemetry for impedance | Secure electronics; edge computing | TA3: Biocompatible Encapsulation, TA2: Wet Biosensing Chiplets |
| Yide Zhang | University of Colorado Boulder | yide.zhang@colorado.edu | Boulder, CO | My research focuses on optical and photoacoustic imaging, wearable and noninvasive biosensing, compact photonic systems, and signal processing for biomedical applications. I am especially interested in translating optical and photoacoustic sensing methods into practical wearable platforms and in developing new ways to measure physiological and biochemical signals noninvasively. | I am especially interested in partners working on hormones, immune markers, and therapeutic drug monitoring. | TA1: Dry Chiplets unique to Biosensing, TA4: Human Factors Testing or Clinical Trial |
| Yi Zhang | University of Connecticut | yi.5.zhang@uconn.edu | Storrs, CT, CT | (1) Aptamer-based biosensors for real-time molecular sensing (Nano Letters 2022, 22, 9, 3668–3677; Analytical Chemistry 2022, 94, 24, 8605–8617). (2) Liquid-based encapsulation for flexible bioelectronics (Nature Communications 2025, 16, 1019; ACS applied materials & interfaces 2021, 13(28), 33464-33476). | Dry chips and human factor performance | TA2: Wet Biosensing Chiplets, TA3: Biocompatible Encapsulation |
| Christopher Muratore | University of Dayton | cmuratore1@udayton.edu | Dayton, OH | Lithography-free roll to roll fabrication of ultra-sensitive, ultra-fast nano-electronic biosensors | Biochemistry and Physiology expertise | TA1: Dry Chiplets unique to Biosensing, TA2: Wet Biosensing Chiplets |
| Baibhab Chatterjee | University of Florida | chatterjee.b@ufl.edu | Gainesville, FL, USA, FL | Ultra-Low Power Communication through the Human Body (~100X more energy-efficient than Bluetooth, ~30X more secure than Bluetooth due to confinement in the body channel), with up to 100 Mbps data rates (20 Mbps in our current commercial products, from our Industry partner, Ixana). We also have expertise in multi-modal, low-power sensing in voltage/current/time domain. | Electrochemical on-chip sensing to increase the number of modalities. For evaluation (and also for future advancements beyond the initial program), biocompatible packaging, and human-factor testing is also something that we are looking for in potential partners. | TA1: Dry Chiplets unique to Biosensing, TA3: Biocompatible Encapsulation |
| Adam Khalifa | University of Florida | a.khalifa@ufl.edu | Gainesville, FL | Expertise in compact, ultra-low-power ASIC design for biomedical applications. Our work focuses on developing versatile, scalable medical device platforms that can be adapted across multiple sensing and therapeutic use cases. | Chiplet integration and packaging | TA1: Dry Chiplets unique to Biosensing |
| Faheem Ershad | University of Houston | fershad@central.uh.edu | Houston, TX | The Bioelectronic Synergy Lab at UH develops on-skin printed neural interfaces for multimodal electrophysiology and biophysical signal recording. Our conformal, real-time designed skin-mounted platforms enable high-fidelity capture of neural, cardiac, and muscular signals. The lab also develops bioelectronic solutions for tissue engineering, including electroactive scaffolds and flexible sensor integration. We aim to extend our on-skin platforms toward continuous biochemical biomarker sensing. | Seeking collaborators with expertise in wireless flexible printed circuit board (fPCB) design for ultra-low-power data transmission from skin-worn sensors. Ideal partners can miniaturize RF/wireless communication modules onto flexible substrates compatible with conformal on-body form factors. Also welcome TA1 dry chiplet teams with power management or secure communications capabilities, and TA3 partners with biocompatible encapsulation experience for long-term skin-contact devices. | TA2: Wet Biosensing Chiplets, TA3: Biocompatible Encapsulation |
| Cunjiang Yu | University of Illinois at Urbana-Champaign | cunjiang@illinois.edu | Urbana-Champaign, IL | Our team at UIUC is specialized in biosensor, and wet biosensors chiplet design, fabrication, testing both ex vivo and in vivo. We also have extensive expertise in biocompatible encapsulation strategies, reliability and aging testing, etc. | We are looking for teaming with expertise in TA1 and TA4. | TA2: Wet Biosensing Chiplets, TA3: Biocompatible Encapsulation |
| Yuanwei Li | University of Illinois Urbana-Champaign | yuanwei@illinois.edu | Urbana, IL | Scalable photonic chips for biosensing | We are looking for partners for TA1 and TA4 | TA2: Wet Biosensing Chiplets, TA3: Biocompatible Encapsulation |
| Natsumi Komatsu | University of Illinois Urbana-Champaign | komatsu@illinois.edu | Urbana, IL | Our team aims to develop a minimally invasive chiplet platform to continuously monitor cardiovascular status via interstitial fluid, targeting metabolites, small molecules, electrolytes, and proteins. By integrating multivariate sensing with machine-perception models, we aim to infer heart failure status and enable clinically actionable monitoring. Our team includes clinical expertise to support human clinical trials. | We bring expertise in biosensing (TA2) and clinical translation (TA4), and seek partners in chiplet-based device development (TA1) and biocompatible encapsulation (TA3). Key needs include ultra-low-power system design and secure medical communications aligned with TA1. We also welcome collaborators with microneedle or other minimally invasive interstitial fluid access technologies. For TA3, we seek robust hermetic sealing compatible with sensing surfaces, manufacturing, and sterilization. | TA2: Wet Biosensing Chiplets, TA4: Human Factors Testing or Clinical Trial |
| Dmitry Kireev | University of Massachusetts Amherst | dkireev@umass.edu | Amherst, MA | Our lab develops graphene field-effect transistor (GFET) biosensors for ultra-sensitive detection of biomolecules. We can engineer pick-and-place functionalized graphene chiplet 'attachments'. Each of these can be easily functionalized for a target protein, cytokine, or small-molecule. This directly aligns with TA-2: we can create modular, cleanroom-compatible sensing interfaces that can be integrated into chiplet-based wearable (or implantable) biosensing platforms. | We have the unique technology that can be used to cover part of TA-2. We are looking for the partners on all other TAs. | TA2: Wet Biosensing Chiplets |
| Dmitry Kireev | University of Massachusetts Amherst | dkireev@umass.edu | Amherst, MA | We develop ultra sensitive graphene field-effect transistor (GFET) biosensors. They can be made in the cleanroom, with modular approach, functionalized with any target, pick-and-placed - as chiplet 'attachments'. Targets can be proteins, cytokines, or small-molecules. Can be integrated into chiplet-based wearable (or implantable) biosensing platforms. | We have the technology to cover TA-2. We are looking for the partners on all other TAs. | TA2: Wet Biosensing Chiplets |
| gang han | university of massachusetts Medical school | gang.han@umassmed.edu | worcester, MA | Our organization develops advanced nanomaterials, photonic biointerfaces, and translational devices for biosensing, imaging, drug delivery, and wireless biological control. Current focus areas include molecular sensing, optical nanotransducers, wearable and implantable systems, and smart human contact lenses for vision enhancement, health monitoring, and ocular drug delivery. | We seek teaming partners with strengths in wearable/implantable or ingestible device engineering, biosensor integration, microelectronics, low-power wireless communication, biocompatible packaging, biomarker assay development, and clinical validation. We are especially interested in collaborators who can help translate advanced nano/optical sensing concepts into robust, human-use platforms. | TA3: Biocompatible Encapsulation, TA2: Wet Biosensing Chiplets |
| Dennis Sylvester | University of Michigan | dmcs@umich.edu | Ann Arbor, MI | Ultra-low power ICs for biomedical applications including power management, analog front-ends and data converters, neural network classifiers, and other key building blocks optimized for the unique constraints of biosensing. | Encapsulation/packaging and use-case expertise, especially the latter. We specialize in taking challenging application-driven constraints and mapping them to novel circuit implementations meeting required specifications. | TA1: Dry Chiplets unique to Biosensing, TA2: Wet Biosensing Chiplets |
| Xudong Fan | University of Michigan | xsfan@umich.edu | Ann Arbor, MI | My lab has developed highly miniatured micro-gas chromatography device (900 g, 1 L in volume) that are being used for wearable (beat-mounted currently) body odor detection to monitor various diseases. We can shrink the size down further significantly (about 100 g). We have also developed algorithms to analyze the body odor detected by our micro-GC. | TA1, TA3, and TA4 | TA2: Wet Biosensing Chiplets |
| Qingfeng Zhai | University of New South Wales Sydney | qingfeng.zhai@unsw.edu.au | Sydney, Australia | Our research focuses on electrochemical biosensors and wearable sensing technologies for real-time health and environmental monitoring. We develop nanoengineered sensing interfaces, flexible and wearable biosensing and energy devices, and advanced electrochemical platforms to enable sensitive, selective, and continuous detection of biomarkers and chemical signals in complex environments. | We seek collaborative partners with complementary expertise in materials science, device engineering, data analytics, and clinical or industry translation. Ideal partners contribute to advancing electrochemical biosensors and wearable sensing systems, including flexible electronics, microfabrication, and real-world validation, to accelerate scalable, impactful solutions for healthcare and environmental monitoring. | TA2: Wet Biosensing Chiplets, TA1: Dry Chiplets unique to Biosensing |
| Wubin Bai | University of North Carolina at Chapel Hill | wbai@unc.edu | Chapel Hill, NC | My research focuses on both fundamental and applied study of soft materials, nanomaterials, and integrated systems, including assembly and manufacturing approaches to enable hybrid integration of multimaterials towards high-performance biosensors and healthcare wearables, the development of new technology that can intelligently immerse electronics and photonics into biological systems, and the creation of new tools and devices to address unmet clinical needs and improve human healthcare. | Experts with relevant animal models as testbeds | TA1: Dry Chiplets unique to Biosensing, TA3: Biocompatible Encapsulation |
| Jingping Nie | University of North Carolina at Chapel Hill | jingping@unc.edu | Chapel Hill, NC | We are a clinical-anchored team developing bio-integrated, multimodal sensing systems for continuous, real-world health monitoring. | Ideal potential teaming partners include chiplet design, advanced packaging, and ultra-low-power IC systems. | TA4: Human Factors Testing or Clinical Trial, TA3: Biocompatible Encapsulation |
| Yanliang Zhang | University of Notre Dame | yzhang45@nd.edu | South Bend, IN | wearable sensors for monitoring physical conditions and biomarkers; wearable thermoelectric energy harvesting devices | wearable sensors to monitor biomarkers, and wireless circuit design | TA2: Wet Biosensing Chiplets, TA1: Dry Chiplets unique to Biosensing |
| Calin Plesa | University of Oregon | calin@uoregon.edu | Eugene, OR | We engineer modular biosensing systems based on chimeric histidine kinase receptors that detect diverse ligands. Our work focuses on expanding recognition diversity, enabling soluble (membrane-independent) formats, and reprogramming response regulators to drive optical or electrical outputs. | We are looking for partners developing strategies for direct integration with chip-compatible surfaces and scalable, multiplexed sensing architectures aligned with chiplet-based biosensing. | TA2: Wet Biosensing Chiplets, TA3: Biocompatible Encapsulation |
| Umit Ogras | University of Wisconsin-Madison | uogras@wisc.edu | Madison, WI | https://elab.ece.wisc.edu/research/fhe/ | Biosensor design and fabrication. | TA4: Human Factors Testing or Clinical Trial |
| Binbin Ying | UT Southwestern Medical Center | sjtuybb@gmail.com | Dallas, TX | N/A | N/A | TA2: Wet Biosensing Chiplets, TA4: Human Factors Testing or Clinical Trial |
| John Bogdan | Valaria Technical Consultants | jbogdan@valtechconsultants.com | Westminster, MD | Our organization primarily focuses on infectious disease and inflammation, detection and therapeutics to treat | We provide services to assist investigators obtain non-dilutive funding using our SMEs in these fields and we establish partnerships for collaborations towards a final solution | TA4: Human Factors Testing or Clinical Trial, TA3: Biocompatible Encapsulation |
| John Bogdan | Valaria Technical Consultants | jbogdan@valtechconsultants.com | Innowise-Warsaw, Poland US offices St. Petersburg, FL with Valaria Technical MD US-based Co, MD | We represent a software developer for telemedicine and telehealth applications and integration of transmitted data into visual dashboards on personal and corporate smart phones in a user-friendly platform. We have experience reviewing US military biosensor development and placement on the body for functionality and accuracy, assessing clinical diagnostic parameters and plans for communication of real-time data across military chain of command. | We would like to team with biosensor partners to help develop a robust data capture, analysis and display/visualization method that is universal, easy to use and more importantly conveys accurate results and advice to the end user like the patient, doctors, nurses, military leaders in DOD and public health officials in HHS | TA4: Human Factors Testing or Clinical Trial |
| Xiaoguang Dong | Vanderbilt University | xgdong2013@gmail.com | Nashville, TN | We are developing battery-free, wireless sensing devices designed for wearable, implantable, and ingestible applications. These systems are powered and interrogated through magnetic fields, enabling both energy transfer and communication without onboard batteries. Our platform leverages advanced manufacturing approaches—including precision laser processing, micromolding, and nanoscale 3D printing—to enable scalable fabrication of miniaturized, high-performance systems. | Teams working on biosensors. | TA1: Dry Chiplets unique to Biosensing, TA3: Biocompatible Encapsulation, TA2: Wet Biosensing Chiplets, TA4: Human Factors Testing or Clinical Trial |
| Cindy Yang Yi | Virginia Tech | yangyi8@vt.edu | Alexandria, VA | Our research focuses on energy‑efficient AI and neuromorphic integrated circuits, radiation‑tolerant architectures, and mixed‑signal systems for real‑time sensing and inference. We develop spiking neural network accelerator platforms and advanced signal‑processing pipelines to enable scalable, high‑fidelity biosensing and seamless integration with next‑generation wearable and implantable systems. | We seek partners with expertise in biosensing materials, microfluidics, dry‑chiplet integration, wearable platforms, and secure data pipelines. Ideal collaborators bring strong translational capabilities, clinical or field‑testing pathways, and complementary strengths in system prototyping, manufacturing, and real‑world deployment. | TA1: Dry Chiplets unique to Biosensing |
| Chenyue Wang | Virginia Tech | chenyue@vt.edu | Alexanderia, VA | neuromorphic hardware and advanced machine learning algorithms | Material scientists, Bioelectronic developers, Electricity-based bioassay developer | TA4: Human Factors Testing or Clinical Trial, TA3: Biocompatible Encapsulation |
| Vahulabaranan Rajagopalan | Yale University | vahulabaranan.rajagopalan@yale.edu | New Haven, CT | The Yale Clinical Neuroscience Group for Neuroanalytics (YNN) and BioSense lab are engaged in the development of sensors and monitoring solutions for the long-term study of neurological and psychiatric disorders. | Teaming partners: We are looking for partners for role 3: a group specialized in biocompatible encapsulation. | TA1: Dry Chiplets unique to Biosensing, TA2: Wet Biosensing Chiplets |